Prescription Medicines
DapazinSM SR Tab. 10/100/1000mg
- Product Category
- diabetes medication
- Active Ingredients
- Dapagliflozin, sitagliptin, metformin
- Appearance
- Yellow to dark yellow, oval-shaped, biconvex, sustained-release film-coated tablets
- Reimbursement Code
- 648105170
01 / 02
1. Composition and Strength : 1 tablet
- Active ingredients:
Dapagliflozin propanediol hydrate (in-house specification) · · · · · · · 12.3mg (10mg as dapagliflozin)
Sitagliptin hydrochloride hydrate (in-house specification) · · · · · · · · 113.4mg (100mg as sitagliptin)
Metformin hydrochloride (BP) · · · · · · · · 1000mg
- Additives: Anhydrous calcium hydrogen phosphate, microcrystalline cellulose, magnesium stearate, Opadry yellow (85F12372), sodium carboxymethyl cellulose, colloidal silicon oxide, croscarmellose sodium, hydroxypropyl cellulose, hypromellose
2. Effectiveness
This drug is administered as an adjunct to diet and exercise therapy to improve glycemic control in patients with type 2 diabetes who are suitable for combined administration of dapagliflozin, sitagliptin, and metformin.
3. Dosage and dosage
In anti-diabetic therapy, the recommended dose of this drug is 10 mg for dapagliflozin and 100 mg for sitagliptin, and the dosage for extended-release metformin hydrochloride is determined in consideration of each patient's current treatment regimen, effectiveness, and tolerability in a range not exceeding 2000 mg.
This drug is taken once a day in the evening with a meal to reduce adverse gastrointestinal reactions caused by metformin hydrochloride. If the dose of metformin hydrochloride needs to be adjusted, adjust the dose step by step.
Patients taking this 10/100/1000 mg sustained-release tablet should take one tablet once a day.
Patients taking this drug and 5/50/1000 mg sustained-release tablets should take 2 tablets once a day simultaneously. If sufficient blood sugar control cannot be achieved with the combination therapy of metformin hydrochloride and sitagliptin, administer dapagliflozin 10 mg sitagliptin 100 mg as the starting dose of this drug and the dose of metformin hydrochloride being taken or a dose therapeutically close to it.
For patients switching from dapagliflozin, sitagliptin, and metformin hydrochloride combination therapy to this drug, the dose of this drug is the existing dose of each component.
The safety and effectiveness of this drug have not been specifically evaluated in patients switching to this drug from other hypoglycemic agents. Any changes in the treatment of patients with type 2 diabetes should be made under careful monitoring because they may cause changes in glycemic control.
To maintain its sustained-release properties, this medication should be swallowed without breaking, crushing, grinding, or chewing. This medication may be incompletely dissolved and excreted in the feces. It is not known whether the substance excreted in feces contains the active ingredient of the drug. If the patient repeatedly reports that this drug has been found in the stool, the healthcare provider should evaluate whether blood sugar is adequately controlled (see Precautions for Use, Section 5. General Precautions).
special group
Patients with renal impairment
Since the effectiveness and safety of this drug depend on renal function and dose adjustment is necessary depending on renal function, it is recommended to periodically evaluate renal function before and after administration of this drug.
No dose adjustment is necessary for patients with mild renal impairment.
In patients with an estimated glomerular filtration rate (eGFR) of 45 mL/min/1.73 m2 or more but less than 60 mL/min/1.73 m2, if the drug is well tolerated and does not have other symptoms that may increase the risk of lactic acidosis, it can be used by adjusting the dose of metformin hydrochloride, one of the components of this drug. The starting dose of sustained-release metformin hydrochloride is 500 mg or 750 mg once a day, so treatment with this drug should not be started. The maximum daily dose of metformin hydrochloride is 1000 mg.
If the estimated glomerular filtration rate (eGFR) falls below 45 mL/min/1.73 m2, administration of this drug should be discontinued immediately. Renal function should be assessed every 3 to 6 months.
4. Precautions for use
1. Warning
1) Sitagliptin
(1) Hypersensitivity reaction
Severe hypersensitivity reactions have been reported in patients receiving post-marketing sitagliptin, including anaphylaxis, angioedema, and exfoliative skin disorders, including Stevens-Johnson syndrome. Because they are voluntarily reported from an unspecified population, it is generally not possible to reliably estimate their incidence or establish a causal relationship with drug exposure. The onset of this reaction occurred within the first 3 months of drug treatment and has also been reported after the first dose. If hypersensitivity reaction is suspected, discontinue this drug, evaluate other potential reasons for the occurrence, and implement other diabetes treatment (see 2. Do not administer to the following patients and 4. Adverse reactions, 2) Sitagliptin, (2) Post-marketing adverse reactions).
(2) Pancreatitis
Acute pancreatitis, including fatal/non-fatal hemorrhagic or necrotizing pancreatitis, has been reported in patients treated with sitagliptin (see section 4. Adverse reactions, 2) Sitagliptin). After starting treatment with this drug, carefully observe whether symptoms of pancreatitis appear. If pancreatitis is suspected, administration of this drug and other suspected drugs should be discontinued.
2) Metformin
(1) In rare cases, severe lactic acidosis or hypoglycemia may occur. Cases of death due to lactic acidosis have been reported.
2. Do not administer to the following patients
1) Patients with known hypersensitivity to this drug or its ingredients
2) Patients with moderate (stage3b) or higher renal impairment (creatinine clearance <45mL/min or glomerular filtration rate <45mL/min/1.73m2), acute conditions that may affect renal function such as dehydration, serious infection, cardiovascular collapse (shock), acute myocardial infarction, and sepsis.
3) Patients with acute and unstable heart failure
4) Patients undergoing tests that involve intravenous administration of radioiodine contrast material (e.g. intravenous urography, intravenous cholangiography, angiography, computed tomography using contrast media, etc.) (can cause acute renal failure, and are associated with lactic acidosis in patients receiving this drug. Therefore, among patients scheduled for such tests, if the glomerular filtration rate is >60ml/min/1.73m2, at least at the time of the test or in advance The drug must be discontinued, and re-administration is not possible within 48 hours. In patients with moderate renal impairment (glomerular filtration rate 45-60 ml/min/1.73 m2), re-administration is not possible within 48 hours after renal function is re-evaluated. Treatment is resumed only after this.)
5) Patients with acute or chronic metabolic acidosis, including type 1 diabetes, lactic acidosis, diabetic ketoacidosis with or without coma, and patients with a history of ketoacidosis [Type 1 diabetes and diabetic ketoacidosis are treated with insulin.]
6) Diabetic precoma
7) In patients with severe infections or severe traumatic systemic disorders, treatment with this drug should be temporarily stopped and treatment should be restarted when the patient's oral intake is restored and renal function is found to be normal.
8) In the case of surgical procedures (excluding minor surgeries where there are no restrictions on food and fluid intake), this drug should be temporarily stopped 48 hours before surgery, and treatment should be restarted at least 48 hours after renal function is confirmed to be normal.
9) Patients with malnutrition, starvation, weakness, pituitary dysfunction, or adrenal dysfunction
10) Impaired liver function (since impaired liver function is associated with some cases of lactic acidosis, administration of this drug should generally be avoided in patients with clinical or laboratory evidence of liver disease), acute or chronic diseases that may cause tissue hypoxia such as respiratory failure, acute myocardial infarction, and shock, excessive alcohol intake, and patients with gastrointestinal disorders such as dehydration, diarrhea, and vomiting.
11) Pregnant women at risk of placental insufficiency, preeclampsia, and intrauterine growth retardation (see section 7. Administration for pregnant and lactating women)
3. Administer with caution to the following patients:
1) Administration in patients with decreased body volume and renal dysfunction
Dapagliflozin may cause a decrease in intravascular blood volume, which may manifest as symptomatic hypotension or sudden and temporary changes in creatinine. In foreign post-marketing surveillance, acute kidney injury was reported in patients receiving SGLT-2 inhibitors, including dapagliflozin, and some required hospitalization and dialysis. The risk of decreased blood volume or hypotension may increase in patients with renal dysfunction (eGFR less than 60mL/min/1.73m2?), the elderly, and those using loop diuretics. For patients with these characteristics, it is necessary to evaluate body fluid status and renal function before starting dapagliflozin administration, and after starting administration, monitor symptoms and signs of hypotension and renal function.
The glucose-lowering efficacy of dapagliflozin depends on renal function. Efficacy is reduced in patients with moderate renal impairment, and dapagliflozin is not recommended solely for glycemic control in patients with type 2 diabetes and an eGFR below 45 mL/min/1.73 m². Among patients with moderate renal impairment, elevated creatinine, phosphorus and parathyroid hormone (PTH) levels and hypotension were reported more frequently with dapagliflozin than with placebo.
Sitagliptin is excreted by the kidneys. In order to reach blood levels similar to those in patients with normal renal function, low doses are recommended in patients with a glomerular filtration rate [eGFR] <45 mL/min/1.73 m2 and in patients with end-stage renal disease (ESRD) requiring hemodialysis or peritoneal dialysis, so this drug is not administered.
Metformin is excreted by the kidneys, and the risk of metformin accumulation and lactic acidosis increases with the degree of renal dysfunction. Therefore, patients with serum creatinine levels above the upper limit of normal for their age should not take this drug.
2) The following patients or conditions (there is a possibility of lactic acidosis and hypoglycemia)
(1) Irregular meal intake, insufficient meal intake
(2) Intense muscle exercise
(3) Patients taking interacting drugs
4. Adverse reactions
1) Dapagliflozin
(1) Summary of safety profile
In clinical studies of patients with type 2 diabetes, more than 15,000 patients received dapagliflozin.
Safety and tolerability were assessed through a predefined pooled analysis of 13 short-term (up to 24 weeks) placebo-controlled trials involving 2,360 patients administered 10 mg of dapagliflozin and 2,295 patients administered placebo.
In the clinical trial to evaluate the cardiovascular effects of dapagliflozin in patients with type 2 diabetes (DECLARE), 8,574 people were administered dapagliflozin 10 mg and 8,569 people were administered placebo, and the median exposure period was 48 months. There were a total of 30,623 patient-years of dapagliflozin exposure.
The most commonly reported adverse reactions throughout clinical studies were genital infections.
(2) List of adverse reactions
The following adverse reactions were observed in placebo-controlled clinical trials. There were no dose-related adverse reactions. The adverse reactions listed below are classified according to frequency and organ system (SOC). Frequency of presentation was defined as follows: very common (≥ 1/10), common (≥ 1/100 to <1/10), uncommon (≥ 1/1,000 to <1/100), rare (≥ 1/10,000 to <1/1,000), very rare (< 1/10,000), and unknown (cannot be assessed from available data).
*Table 1: Refer to attached document
(3) Description of specific adverse reactions
① Vulvovaginitis, balanitis and related genital infections
Pooled safety data from 13 clinical trials showed that vulvovaginitis, balanitis, and related genital infections were reported in 5.5% and 0.6% of subjects receiving dapagliflozin 10 mg and placebo, respectively. Most infections were mild to moderate, subjects responded to initial standard treatment, and rarely led to discontinuation of dapagliflozin. These infections were more common in women (8.4% and 1.2% in the dapagliflozin and placebo groups, respectively), and subjects with a prior medical history were more likely to have recurrent infections.
In the DECLARE clinical trial, the number of serious adverse events of genital infection was very small and evenly distributed (2 patients each in the dapagliflozin and placebo groups).
In the DAPA-HF clinical trial, no serious adverse events of genital infection were reported in the dapagliflozin group and one case was reported in the placebo group. There were 7 patients (0.3%) in the dapagliflozin group and none in the placebo group who discontinued treatment due to adverse events of genital infection.
In the DAPA-CKD clinical trial, serious adverse events of genital infection were reported in 3 cases (0.1%) in the dapagliflozin group and none in the placebo group. There were 3 patients (0.1%) in the dapagliflozin group and none in the placebo group who discontinued treatment due to adverse events of genital infection. In patients without diabetes, no serious adverse events of genital infection or adverse events leading to discontinuation of treatment were reported.
② Low blood sugar
The frequency of hypoglycemia in clinical trials in patients with diabetes depended on the type of baseline therapy used in each trial.
In additional combination studies of dapagliflozin alone, metformin, or sitagliptin (metformin alone or in combination), the frequency of mild hypoglycemic episodes was similar (<5%) between treatment groups, including placebo, up to 102 weeks of treatment. In a comprehensive analysis of safety information from 1,169 patients evaluated for dapagliflozin and saxagliptin combination therapy, the overall incidence of hypoglycemia was low at 24 weeks (≤1.8% in all groups).
In all trials, major hypoglycemic events were uncommon and equivalent between dapagliflozin and placebo groups. The incidence of hypoglycemia was higher in studies with the addition of sulfonylurea and in studies with the addition of insulin.
In the glimepiride add-on study, mild hypoglycemic episodes were reported more frequently at weeks 24 and 48 in those receiving dapagliflozin 10 mg and glimepiride (6.0% and 7.9%, respectively) compared to those receiving placebo and glimepiride (2.1% and 2.1%, respectively).
In the insulin add-on combination study, major hypoglycemic episodes were reported in 0.5% and 1.0% of patients at weeks 24 and 104, respectively, in patients administered dapagliflozin 10 mg in combination with insulin, and 0.5% were reported at weeks 24 and 104 in patients administered placebo in combination with insulin. Minor hypoglycemic episodes were reported in patients administered dapagliflozin 10 mg in combination with insulin. It was reported in 40.3% and 53.1% at weeks 24 and 104, respectively, and in patients receiving placebo with additional insulin, it was reported in 34.0% and 41.6%.
In an add-on therapy trial of metformin and sulfonylureas, no major episodes of hypoglycemia were reported by week 24. Mild hypoglycemic episodes were reported in 12.8% of subjects receiving dapagliflozin 10 mg plus metformin and sulfonylurea and in 3.7% of subjects receiving placebo plus metformin and sulfonylurea.
The DECLARE trial showed that dapagliflozin therapy compared with placebo did not increase the risk of major hypoglycemic events. Major hypoglycemic events were reported in 58 patients (0.7%) in the dapagliflozin group and in 83 patients (1.0%) in the placebo group.
In the DAPA-HF clinical trial, major hypoglycemic events were reported in 4 patients (0.2%) each in the dapagliflozin and placebo groups, and occurred only in patients with type 2 diabetes.
In the DAPA-CKD clinical trial, major hypoglycemic events were reported in 14 patients (0.7%) in the dapagliflozin group and 28 patients (1.3%) in the placebo group, and were observed only in patients with type 2 diabetes.
③ Reduction in body fluid volume
According to pooled safety data from 13 clinical trials, drug reactions suggestive of volume loss (including dehydration, hypovolemia, or hypotension) were reported in 1.1% and 0.7% of subjects receiving dapagliflozin 10 mg and placebo, respectively; Serious reactions, occurring in less than 0.2% of subjects, were evenly distributed between the dapagliflozin 10 mg and placebo groups.
In the DECLARE clinical trial, the number of patients who developed adverse events suggesting a decrease in body fluid volume was evenly distributed among treatment groups: 213 (2.5%) in the dapagliflozin group and 207 (2.4%) in the placebo group. Serious adverse events were reported in 81 patients (0.9%) in the dapagliflozin group and 70 patients (0.8%) in the placebo group. Adverse events were generally evenly distributed between treatment groups across subgroups, including age, use of diuretics, blood pressure, and use of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers. In the patient population with a baseline estimated glomerular filtration rate (eGFR) of less than 60 mL/min/1.73 m2?, 19 serious adverse events suggesting decreased body fluid volume were reported in 19 cases in the dapagliflozin group and 13 cases in the placebo group.
In the DAPA-HF clinical trial, the number of patients with adverse events suggesting a decrease in body fluid volume was 170 (7.2%) in the dapagliflozin group and 153 (6.5%) in the placebo group. The number of patients with serious adverse events suggesting volume loss was lower in the dapagliflozin group (23 patients [1.0%]) than in the placebo group (38 patients [1.6%]). Similar results were observed across subgroups including age, presence of diabetes at baseline, baseline eGFR, and systolic blood pressure.
In the DAPA-CKD clinical trial, the number of patients with adverse events suggesting a decrease in body fluid volume was 120 (5.6%) in the dapagliflozin group and 84 (3.9%) in the placebo group. The number of patients with serious adverse events suggesting a decrease in body fluid volume was 16 (0.7%) in the dapagliflozin group and 15 (0.7%) in the placebo group.
④ Diabetic ketoacidosis
In the DECLARE clinical trial (median dapagliflozin exposure period of 48 months), 27 cases of diabetic ketoacidosis were reported in the patient group administered dapagliflozin 10 mg and 12 cases in the placebo group. Occurrence points were evenly distributed throughout the study period. Of the 27 patients who developed diabetic ketoacidosis in the dapagliflozin group, 22 were taking insulin at the time the case occurred. Precipitating factors for diabetic ketoacidosis appeared as expected in the type 2 diabetes patient population (see sections 5. General precautions, 5) Ketoacidosis).
In the DAPA-HF clinical trial, diabetic ketoacidosis cases were reported in 3 patients with type 2 diabetes in the dapagliflozin group and no cases in the placebo group.
In the DAPA-CKD clinical trial, no cases of diabetic ketoacidosis were reported in the dapagliflozin group and two cases of type 2 diabetes were reported in the placebo group.
⑤ Urinary tract infection
Pooled safety data from 13 clinical trials showed that urinary tract infections were reported more frequently in the dapagliflozin 10 mg group compared to the placebo group (4.7% vs 3.5%, respectively). Most infections were mild to moderate, subjects responded to initial standard treatment, and rarely led to discontinuation of dapagliflozin. These infections were more common in women, and subjects with a previous medical history were more likely to develop recurrent infections.
In the DECLARE clinical trial, 79 cases (0.9%) of serious adverse events of urinary tract infection were reported in the dapagliflozin 10 mg treatment group, which was less frequent than the 109 cases (1.3%) in the placebo group.
In the DAPA-HF clinical trial, the number of patients who experienced serious adverse events of urinary tract infection was small, with no significant difference between the two groups: 14 patients (0.6%) in the dapagliflozin group and 17 patients (0.7%) in the placebo group. There were 5 patients (0.2%) in each of the dapagliflozin and placebo groups who discontinued treatment due to adverse events of urinary tract infection.
In the DAPA-CKD clinical trial, the number of patients who experienced serious adverse events of urinary tract infection was 29 (1.3%) in the dapagliflozin group and 18 (0.8%) in the placebo group. There were 8 patients (0.4%) in the dapagliflozin group and 3 (0.1%) in the placebo group who discontinued treatment due to adverse events of urinary tract infection.
⑥ Increased creatinine
Adverse reactions associated with increased creatinine were classified as decreased renal creatinine clearance, renal impairment, increased blood creatinine, and decreased glomerular filtration rate. According to pooled safety data from 13 clinical trials, these adverse reactions were reported in 3.2% and 1.8% of subjects receiving dapagliflozin 10 mg and placebo, respectively. In normal subjects or patients with mild renal failure (eGFR 60 mL/min/1.73 m2? or higher), these adverse reactions were reported in 1.3% and 0.8% of patients receiving dapagliflozin 10 mg and placebo, respectively. These adverse reactions were reported more frequently in patients with an eGFR greater than 30 mL/min/1.73 m2? or less than 60 mL/min/1.73 m2? (18.5% and 9.3% with dapagliflozin 10 mg and placebo, respectively).
In the subsequent evaluation of patients with kidney-related adverse events, changes in serum creatinine of ≤ 0.5 mg/dL from baseline were observed in most patients. Increased creatinine usually occurs transiently during treatment or resolves after treatment is discontinued.
In the DECLARE clinical trial, which included elderly patients and patients with renal impairment (eGFR less than 60mL/min/1.73m2?), eGFR decreased over time in both the dapagliflozin group and the placebo group. After 1 year, the average eGFR was slightly lower in the dapagliflozin group, and after 4 years, the average eGFR in the dapagliflozin group was slightly higher than the placebo group.
In the DAPA-HF clinical trial, eGFR decreased over time in both the dapagliflozin group and the placebo group. The initial decrease in mean eGFR was -4.3 mL/min/1.73 m2 in the dapagliflozin group and -1.1 mL/min/1.73 m2 in the placebo group. At 20 months, the change in eGFR from baseline was similar between treatment groups (dapagliflozin group -5.3 mL/min/1.73 m2, placebo group -4.5 mL/min/1.73 m2).
In the DAPA-CKD clinical trial, eGFR decreased over time in both the dapagliflozin group and the placebo group. The initial (day 14) decrease in average eGFR was -4.0 mL/min/1.73 m2 in the dapagliflozin group and -0.8 mL/min/1.73 m2 in the placebo group. At 28 months, the change in eGFR compared to baseline was -7.4mL/min/1.73m2 in the dapagliflozin group and -8.6mL/min/1.73m2 in the placebo group.
⑦ Perineal gangrene (Fournier’s gangrene)
During post-marketing surveillance, cases of Fournier's gangrene have been reported in patients receiving SGLT2 inhibitors, including dapagliflozin (see 5. General precautions, 11) Perineal gangrene (Fournier's gangrene).
In the DECLARE clinical trial involving 17,160 patients with type 2 diabetes and a median exposure period of 48 months, a total of 6 cases of Fournier's gangrene were reported, including 1 case in the dapagliflozin group and 5 cases in the placebo group.
(4) Post-marketing surveillance
The following are additional adverse drug reactions confirmed after the marketing of dapagliflozin. This adverse drug reaction was reported voluntarily from an uncharacteristic large population, so it is not possible to reliably predict its incidence.
- Ketoacidosis (including diabetic ketoacidosis)
- Urosepsis and pyelonephritis
- Acute kidney injury and renal dysfunction
- Rash: Rash includes the following representative terms in order of frequency in clinical studies: rash, generalized rash, pruritic rash, macular rash, maculopapular rash, pustular rash, bullous rash, and erythematous rash. In active-controlled and placebo-controlled clinical studies (5,936 people in the dapagliflozin group, 3,403 people in all control groups), the frequency of rash was similar in the dapagliflozin group (1.4%) and all control groups (1.4%) and was ‘common.’
(5) Domestic post-marketing survey results
As a result of a post-marketing survey conducted on 3,027 people over 6 years for re-examination in Korea, the occurrence rate of adverse events was reported to be 26.59% (805/3,027 people, total 1,122 cases) regardless of causal relationship. Among these, serious adverse events unrelated to a causal relationship and serious adverse drug reactions for which a causal relationship cannot be ruled out are listed in the table below according to the frequency of occurrence.
*Table: Refer to attached document
In addition, unexpected adverse events unrelated to causal relationships and unexpected adverse drug reactions for which causal relationships cannot be ruled out are listed in the following table according to the frequency of occurrence.
*Table: Refer to attached document
2) Sitagliptin
(1) Clinical trials
① Because clinical trials are conducted under wide and diverse conditions, the incidence of adverse reactions observed in clinical trials cannot be directly compared to the rates in clinical trials of other drugs, and cannot reflect the rates observed under actual use environments.
In clinical trials of sitagliptin, when sitagliptin was administered as monotherapy or combination therapy (metformin or pioglitazone or rosiglitazone and metformin), the incidence of adverse reactions and hypoglycemia was generally similar to that reported for placebo. Cases where treatment was discontinued due to adverse reactions were similar to those in the placebo group.
During glimepiride or glimepiride and metformin combination therapy, the frequency of adverse reactions in the sitagliptin group was higher than the placebo group (Table 4). This is partly due to the high incidence of hypoglycemia in the sitagliptin administration group. Discontinuation of treatment due to adverse reactions was similar to that in the placebo group.
Two placebo-controlled monotherapy studies conducted for 18 and 24 weeks included groups receiving sitagliptin 100 mg and 200 mg daily and placebo. Five additional placebo-controlled combination therapy studies administered 100 mg of sitagliptin or placebo daily in combination with stable doses of metformin, pioglitazone, rosiglitazone, and metformin, glimepiride (±metformin), or insulin (±metformin), respectively.
In these clinical trials, except for hypoglycemia and regardless of causality assessment, adverse reactions reported at a frequency of 5% or more among patients taking sitagliptin 100 mg daily for 18 weeks and more frequently than placebo are listed in Table 2. The frequency of occurrence of hypoglycemia is shown in Table 4.
Table 2. Placebo-controlled clinical trials with sitagliptin monotherapy or in combination (pioglitazone, or rosiglitazone and metformin, or glimepiride (±metformin)): Adverse events, excluding hypoglycemia, reported at a frequency greater than 5% and more frequently than placebo, regardless of causality assessment†
*Table 2: Refer to attached document
† ITT (Intent-to-treat) subject group
In patients who received sitagliptin and metformin in combination for 24 weeks, there were no adverse reactions reported at a frequency of more than 5% and more frequently than placebo, regardless of causality assessment.
In patients who received sitagliptin in combination with a stable dose of insulin (±metformin) for 24 weeks, there were no adverse reactions except hypoglycemia, which was reported at a frequency of more than 5% and more frequently than placebo, regardless of causality assessment (see Table 4 for hypoglycemia). In patients receiving additional sitagliptin during another 24-week insulin intensification period (±metformin), the adverse reaction reported at a frequency greater than 5% and more frequently than placebo, regardless of causality assessment, was diarrhea (sitagliptin 5.2%; placebo 3.3%).
In patients receiving sitagliptin in combination with rosiglitazone and metformin for 54 weeks, adverse reactions reported at a frequency of 5% or more and more frequently than placebo, regardless of causality assessment, were: upper respiratory tract infection (sitagliptin 15.5%, placebo 6.2%), nasopharyngitis (11.0%, 9.3%), peripheral edema (8.3%, 5.2%), and headache. (5.5%, 4.1%).
As a result of a comprehensive analysis of two monotherapy clinical trials, a clinical trial with additional combination therapy with metformin, and a clinical trial with additional combination therapy with pioglitazone, the occurrence of specific gastrointestinal adverse reactions in patients treated with sitagliptin was as follows: abdominal pain (sitagliptin 100 mg 2.3%, placebo 2.1%), nausea (sitagliptin 100 mg 1.4%, placebo 0.6%), Diarrhea (sitagliptin 100mg 3.0%, placebo 2.3%)
In a placebo-controlled factorial design clinical trial conducted for 24 weeks, adverse reactions reported at a frequency of 5% or more or more frequently than placebo, regardless of causality assessment, upon initial co-administration of sitagliptin and metformin are shown in Table 3.
Table 3. Initial combination therapy with sitagliptin and metformin: Adverse reactions reported at a frequency of 5% or more and more frequently than sitagliptin alone, metformin alone, or placebo, regardless of causality assessment†
*Table 3: Refer to attached document
† ITT (Intent to treat) subject group
‡ Integrated data of patients receiving low and high doses of metformin
No clinically significant changes in vital signs or ECG (including QTc interval) were observed with sitagliptin administration.
② Pancreatitis
When the results of 19 double-blind clinical trials of 10,246 patients randomly assigned to sitagliptin 100 mg/day (N=5429) or the corresponding control group (active comparator or placebo) (N=4817) were pooled and analyzed, the incidence of acute pancreatitis in each group was 0.1 per 100 patient-years (in the sitagliptin group) reported in 4 patients out of 4708 patient-years and in the control group in 4 patients out of 3942 patient-years). In the TECOS cardiovascular safety trial, the incidence of acute pancreatitis was reported to be 0.11 (23/7,332, 25 cases) per 100 patient-years in the sitagliptin group and 0.06 (12/7,339, 17 cases) per 100 patient-years in the placebo group. (See 1. Warning, 1) Sitagliptin, (2) Pancreatitis section, and TECOS Cardiovascular Safety Clinical Trial section)
③ TECOS cardiovascular safety clinical trial (TECOS: Trial Evaluating Cardiovascular Outcomes with Sitagliptin)
The intent-to-treat (ITT) arm of the sitagliptin cardiovascular safety clinical trial included 7,332 patients who received sitagliptin 100 mg daily (or 50 mg daily if eGFR ≥ 30 and < 50 mL/min/1.73 m2 at baseline) and 7,339 patients who received placebo. In this trial, sitagliptin or placebo was administered in addition to usual treatment in each country related to HbA1c and cardiovascular (CV) risk factors. Sitagliptin administration did not increase the risk of hospitalization due to major cardiovascular disease or heart failure. The reported incidence of serious adverse reactions was similar at 12.7% in the sitagliptin group and 12.4% in the placebo group.
Severe hypoglycemia was reported in 2.2% of the sitagliptin group (160 patients; 0.78 per 100 patient-years) and 1.9% of the placebo group (143 patients; 0.70 per 100 patient-years). Among patients receiving insulin and/or a sulfonylurea, the incidence was 2.7% with sitagliptin (138/5,021 patients) and 2.5% with placebo (125/4,931 patients). Among patients not receiving insulin or a sulfonylurea, the incidence was 1.0% with sitagliptin (22/2,311 patients) and 0.7% with placebo (18/2,408 patients). Confirmed acute pancreatitis occurred in 0.3% of the sitagliptin group and 0.2% of the placebo group.
④ Low blood sugar
In all studies (9), hypoglycemic adverse events were based on reports of symptomatic hypoglycemia. Although blood sugar measurement was not necessarily involved, most reports of hypoglycemia (74%) were below 70 mg/dL when measured. When sitagliptin was administered in combination with a sulfonylurea or insulin, the proportion of patients with one or more hypoglycemic adverse events was higher than in the placebo group (see Table 4).
Table 4. Placebo-controlled trials of sitagliptin in combination with glimepiride (±metformin) or insulin (±metformin): reported incidence of hypoglycemia, regardless of causality assessment†
*Table 4: Refer to attached document
† Hypoglycemic adverse events were based on reports of symptomatic hypoglycemia and were not necessarily accompanied by blood glucose measurements; ITT (Intent to treat) group
‡ Based on total number of incidents (a person may report multiple incidents)
§ Severe hypoglycemia was defined as requiring medical attention, reaching a reduced level of consciousness, losing consciousness, or having a seizure.
As a result of a comprehensive analysis of two monotherapy clinical trials, a clinical trial with additional combination therapy with metformin, and a clinical trial with additional combination therapy with pioglitazone, the incidence of hypoglycemia as an adverse reaction in patients administered sitagliptin 100 mg was similar to that of placebo (1.2% for sitagliptin 100 mg, 0.9% for placebo).
In a clinical trial of the combination therapy of sitagliptin, rosiglitazone, and metformin, the incidence of hypoglycemia up to 18 weeks was 2.2% in the sitagliptin group and 0.0% in the placebo group. The incidence up to 54 weeks was 3.9% and 1.0%, respectively.
In a placebo-controlled factorial trial conducted for 24 weeks, the incidence of hypoglycemia during initial co-administration of sitagliptin and metformin was 0.6% in the placebo group, 0.6% in the sitagliptin-only group, 0.8% in the metformin-only group, and 1.6% in the sitagliptin-metformin combination group.
⑤ Laboratory tests
The incidence of laboratory adverse reactions in the group administered 100 mg of sitagliptin was 8.2%, and in the group administered placebo it was 9.8%. In clinical trials, a slight increase in white blood cell count (approximately 200 cells/μL difference compared to placebo administration; average baseline value of approximately 6600 cells/μL) was observed due to an increase in neutrophils. This difference has been shown in many, but not all, studies, and changes in laboratory values are not believed to be clinically relevant.
In a 12-week study, 91 patients with chronic renal impairment and 37 patients with moderate renal impairment were randomly assigned to sitagliptin 50 mg, and 14 patients with the same degree of renal impairment were randomized to placebo. The mean (standard error) increase in serum creatinine was 0.12 mg/dL (0.04) in the sitagliptin group and 0.07 mg/dL (0.07) in the placebo group. The clinical significance of increased serum creatinine compared to placebo is unknown.
⑥ Domestic clinical trial results
The safety and efficacy of sitagliptin were evaluated in a bridging clinical trial conducted in 530 Asians in a multinational, double-blind, randomized, placebo-controlled, parallel group study, of which 95 were Korean. The safety profile of sitagliptin in Koreans was overall similar to that of placebo and did not show significant differences from the results reported in previous clinical trials.
(2) Post-marketing adverse reactions
The following are additional adverse reactions confirmed after the marketing of sitagliptin. Because these adverse reactions are voluntarily reported from an unspecified population, it is generally not possible to reliably predict their frequency or establish a causal relationship with drug exposure. Hypersensitivity reactions, including anaphylaxis, angioedema, rash, urticaria, cutaneous angiitis and exfoliative skin diseases including Stevens-Johnson syndrome (see section 1. Warnings), elevated liver enzymes; Acute pancreatitis, including fatal/non-fatal hemorrhagic or necrotizing pancreatitis (see 1. Warning, 1) Sitagliptin, (2) Pancreatitis); Deterioration of renal function, including acute renal failure (sometimes requiring dialysis); upper respiratory tract infection; nasopharyngitis; constipation; puke; headache; Severe and disabling arthralgia (see section 5. General precautions, section 12) Severe and disabling arthralgia); Bullous pemphigoid (see section 5. General precautions, 13) Bullous pemphigoid); myalgia; Pain in limbs; back pain; interstitial lung disease; pruritus; It is thrombocytopenia. During post-marketing use, rhabdomyolysis was reported when taken with statin drugs. (Domestic clue information analysis and evaluation results)
(3) Domestic post-marketing survey results
① As a result of a use result survey conducted on 3,453 people over 6 years for re-examination in Korea, the incidence of adverse events was reported to be 4.87% (168/3,453 people) [232 cases] regardless of causal relationship, and among these, the incidence of adverse drug reactions for which a causal relationship with sitagliptin could not be ruled out was 1.56% (54/3,453 people). [64 cases] ‘hypoglycemia’ at 0.26% (9 people/3,453 people) [9 cases], ‘indigestion’ and ‘dizziness’ at 0.12% each (4/3,453 people) [4 cases], ‘increased ALT’, ‘AST increase’, ‘diarrhea’, ‘nausea’, and ‘headache’ at 0.09% each (3/3,453 people) [3 cases], etc. It has been reported.
Serious adverse events were 0.12% (4/3,453 people) [5 cases] regardless of causal relationship, with ‘pneumonia’, ‘diabetic complications’, ‘metabolic acidosis’, ‘fall’, and ‘cardiac arrest’ occurring at 0.03% (1/3,453 people) [1 case] each. Among these, the serious adverse drug reaction was ‘diabetic complications’ at 0.03%. (1/3,453 people)[1 case] reported.
Unexpected adverse events were reported at 3.04% (105/3,453 people) [137 cases] regardless of causal relationship, ‘indigestion’ at 0.32% (11/3,453 people) [12 cases], ‘dizziness’ at 0.23% (8/3,453 people) [8 cases], ‘increased blood triglyceride’, and ‘gastritis’. 0.17% (6/3,453 people) [6 cases] were reported, and among these, unexpected adverse drug reactions for which a causal relationship with sitagliptin cannot be ruled out were 0.93% (32/3,453 people) [35 cases], ‘indigestion’ and ‘dizziness’ at 0.12% (4/3,453 people) [4 cases] respectively, ‘increased blood triglycerides’, ‘Increased low-density lipoprotein’ and ‘hyperglycemia’ were reported in the order of 0.06% (2/3,453 people) [2 cases] each.
② As a result of integrated evaluation of the domestic re-examination adverse event and spontaneous side effect reporting data for sitagliptin with the adverse event reporting data reported for all domestically approved drugs at the end of re-examination, the following are newly identified adverse events that were statistically significantly more reported for sitagliptin than those reported for all other drugs. However, this result does not mean that a causal relationship has been proven between the ingredient and the following adverse events.
· Gastrointestinal disorders: indigestion, gastritis
· Metabolic and nutritional diseases: weight loss
· Common cardiovascular diseases: high blood pressure
· Metabolic and nutritional diseases: hypernatremia
· Mental illness: erectile dysfunction
3) Metformin
In post-marketing surveillance and clinical trial results, the side effects reported in patients receiving metformin hydrochloride extended-release tablets were similar in content and severity to the side effects reported in patients receiving metformin hydrochloride immediate-release tablets.
The following side effects may occur when receiving metformin:
Frequency is defined as follows: Very common: >1/10 Common: >1/100, <1/10 Uncommon: >1/1,000, <1/100 Rare: >1/10,000, <1/1,000 Very rare: <1/10,000
(1) Metabolic and nutritional disorders
Common: vitamin B12 deficiency
Very rare: Lactic acidosis (see section 5. General precautions)
(2) nervous system disorders
Common: taste impairment
(3) Gastrointestinal disorders
Very common: Gastrointestinal disorders such as nausea, vomiting, diarrhea, abdominal pain and anorexia (see Section 5. General precautions)
(4) Skin and subcutaneous tissue disorders
Very rarely: erythema, itching, urticaria, rash, etc. may occur. In such cases, discontinue administration.
5. General precautions
1) Lactic acidosis
Lactic acidosis is a rare but serious metabolic complication that occurs due to metformin accumulation during metformin treatment. In 50% of cases, it is fatal. Lactic acidosis occurs frequently in acute renal dysfunction, cardiopulmonary disease, and sepsis. Lactic acidosis may occur when there is significant tissue hypoperfusion and hypoxia and in conjunction with pathophysiological conditions, including diabetes. Lactic acidosis is characterized by increased blood lactic acid concentration (over 5 mmol/L), decreased blood pH, electrolyte imbalance with increased difference between anions, and increased lactic acid/pyruvate ratio. When metformin is believed to be the cause of lactic acidosis, metformin blood levels generally exceed 5 μg/mL.
There are very few reports of the development of lactic acidosis in patients receiving metformin (approximately 0.03 cases per 1,000 patients per year and approximately 0.015 fatal cases per 1,000 patients per year). The reported cases primarily occurred in diabetic patients with significantly reduced renal function, including intrinsic renal disease and renal hypoperfusion, in conditions such as multiple medical and surgical problems and combined administration of many drugs. The risk of lactic acidosis increases with the degree of renal function decline and the patient's age.
In addition, metformin should be discontinued immediately if symptoms related to hypoxia, dehydration, or sepsis appear. If liver function is impaired, the ability to excrete lactic acid may be significantly reduced, so this drug is generally not administered to patients with clinical or laboratory findings of liver disease. Since alcohol has the potential to affect metformin's lactic acid metabolism, acute or chronic excessive intake of alcohol should be avoided while taking this drug.
The onset of lactic acidosis is sometimes difficult to distinguish and is accompanied by nonspecific symptoms such as malaise, myalgia, dyspnea, asthenia, and abdominal pain. If acidosis becomes more severe, a drop in body temperature, hypotension, and resistant bradyarrhythmia may occur. Patients and doctors should be aware of the importance of these symptoms, and patients should notify their doctors immediately if these symptoms occur. Serum electrolytes, ketones, blood sugar, blood pH (<7.35), lactic acid concentration, and blood metformin concentration may also be useful in confirming lactic acidosis. Additionally, if there is a high suspicion of lactic acidosis, necessary measures are taken without expecting a lactic acid measurement result. In particular, be careful because lactic acidosis is likely to occur when the initial dose is increased. Gastrointestinal symptoms often occur early in treatment once the patient has stabilized on a specific dose of metformin, but later gastrointestinal symptoms may be due to lactic acidosis or another serious illness.
Fasting venous plasma lactate concentrations above the upper limit of normal but below 5 mmol/L in patients receiving metformin do not indicate impending lactic acidosis and may be due to other mechanisms, such as poorly controlled diabetes or obesity, excessive physical activity, or technical problems in specimen handling. Lactic acidosis should be suspected in diabetic patients presenting with metabolic acidosis without evidence of ketoacidosis (ketonuria and ketonemia).
Lactic acidosis is a medical emergency requiring hospitalization. If lactic acidosis occurs in a patient taking this drug, the drug should be discontinued immediately and general supportive treatment should be administered immediately. Because metformin is dialyzable (clearance reaching 170 mL/min in good hemodynamic conditions), immediate hemodialysis is recommended to normalize acidosis and remove accumulated drug. This treatment sometimes results in immediate symptom improvement and recovery.
2) Monitoring of renal function
Metformin and sitagliptin are mostly excreted by the kidneys, and the risk of metformin accumulation and lactic acidosis increases depending on the degree of renal dysfunction. The effectiveness of dapagliflozin on blood sugar varies depending on renal function. Patients with serum creatinine levels above the upper limit of normal for their age should not take this drug. Before starting treatment with this drug, and at least annually, renal function should be evaluated and confirmed normal. Patients with creatinine clearance lower than normal and the elderly should have a renal function test performed at least 2 to 4 times a year. If creatinine clearance <45ml/min or glomerular filtration rate <45ml/min/1.73m2), discontinue treatment with this drug. Special caution is needed in situations that may lead to rapid renal function impairment, such as those experiencing dehydration (severe or persistent vomiting or diarrhea) or starting medications that affect renal function (such as antihypertensive drugs or diuretics and nonsteroidal anti-inflammatory drugs (NSAIDs)). In these acute situations, administration of this drug should be discontinued immediately and temporarily.
3) Use in patients at risk of volume loss and/or hypotension
Due to the mechanism of action of dapagliflozin, an increase in urination leading to a slight decrease in blood pressure was observed in clinical studies. This may be more noticeable in patients with very high blood sugar levels.
Caution should be exercised in patients who may be at risk for drug-induced reductions in blood pressure, such as patients receiving antihypertensive treatment and a history of hypotension or elderly patients.
If there are comorbidities that may cause volume loss (e.g., gastrointestinal disease), close monitoring of fluid volume status (e.g., physical examination, blood pressure measurement, and laboratory tests including hematocrit and electrolyte testing) is recommended. For patients exhibiting volume loss, temporary discontinuation of dapagliflozin is recommended until volume loss is restored.
4) Action on the liver
Monitoring of liver enzymes is recommended in all patients prior to initiating therapy with this drug, and thereafter at regular intervals based on the clinical judgment of the physician.
(1) Dapagliflozin
Clinical trial experience in patients with hepatic impairment is limited. Dapagliflozin exposure is increased in patients with severe hepatic impairment.
(2) Metformin
Metformin is contraindicated in patients with hepatic impairment because its use has been associated with some cases of lactic acidosis.
5) Ketoacidosis
Reports of serious, life-threatening ketoacidosis requiring prompt hospitalization have been identified in patients with type 1 and type 2 diabetes treated with SGLT2 inhibitors, including dapagliflozin. Fatal cases of ketoacidosis have been reported in patients treated with dapagliflozin.
Dapagliflozin-associated ketoacidosis may occur even when blood glucose is below 250 mg/dL. Patients treated with dapagliflozin who show signs and symptoms consistent with severe metabolic acidosis should therefore be evaluated for ketoacidosis regardless of their blood glucose level. If ketoacidosis is suspected, discontinue dapagliflozin, assess the patient’s condition and initiate treatment promptly.
Treatment of ketoacidosis may require insulin, fluid, and carbohydrate replacement.
In many post-marketing reports, particularly in patients with type 1 diabetes, the presence or absence of ketoacidosis was not immediately identified and the introduction of treatment was delayed because the observed blood glucose levels were lower than those typically expected for diabetic ketoacidosis (most often less than 250 mg/dL).
Diabetes and ketoacidosis may persist longer than is generally expected, and urinary glucose secretion may persist for up to 3 days after discontinuation of treatment. However, there have been post-marketing reports that diabetes and ketoacidosis persisted for more than 6 days and up to 2 weeks after discontinuation of SGLT2 inhibitor treatment. Symptoms and signs of ketoacidosis are consistent with dehydration and severe metabolic acidosis and include nausea, vomiting, decreased appetite, abdominal pain, malaise, and difficulty breathing. Some reports have identified factors predisposing to ketoacidosis to include reduced insulin dose, acute febrile illness, restricted calorie intake due to illness or surgery, ketogenic diet, pancreatic disorders causing insulin deficiency (e.g., type 1 and 2 diabetes, pancreatitis, or history of pancreatic surgery), and alcohol abuse.
Before starting dapagliflozin treatment, factors that may predispose to ketoacidosis, including decreased insulin secretion, calorie restriction, and alcohol abuse, should be considered. Monitor patients treated with dapagliflozin for the development of ketoacidosis, and consider temporarily discontinuing dapagliflozin administration if clinical situations predisposing to ketoacidosis (e.g., prolonged fasting due to acute illness or surgery) occur.
Inform patients about the risk of diabetic ketoacidosis, its risk factors, signs and symptoms, and the fact that it may occur even when blood glucose is below 250 mg/dL. It is recommended that patients be able to monitor blood ketones and receive education on when monitoring is needed. Patients should seek prompt treatment if ketoacidosis is suspected.
6) Urosepsis and pyelonephritis
Serious urinary tract infections, including urosepsis and pyelonephritis, have been reported post-marketing in patients using dapagliflozin and other SGLT2 inhibitors. SGLT2 inhibitor therapy increases the risk of urinary tract infections. If necessary, evaluate the patient's signs and symptoms of urinary tract infection and promptly treat them.
7) Reproductive infections (including fungi)
Dapagliflozin increases the risk of genital infections (including fungal). Patients with a history of genital infections (including fungal) are more likely to develop genital infections (including fungal). Observe and treat appropriately.
8) Urine laboratory evaluation
Patients receiving dapagliflozin will test positive for urinary glucose due to its mechanism of action.
9) SGLT2 inhibitors such as dapagliflozin may theoretically worsen the condition of patients with underlying bladder diseases that may affect urinary function by increasing urine volume. Therefore, caution is required when prescribing SGLT2 inhibitors such as dapagliflozin to these patients.
10) Lower limb amputation
In long-term clinical studies of other SGLT2 inhibitors in patients with type 2 diabetes, an increase in lower extremity amputations (mainly toes) was observed. It has not been confirmed whether this case applies to the entire series. It is important to discuss routine preventive foot care with patients with diabetes.
11) Perineal gangrene (Fournier’s gangrene)
In post-marketing surveillance of diabetic patients taking SGLT2 inhibitors, rare cases of serious, life-threatening perineal gangrene requiring prompt surgical intervention were reported [4. Adverse reactions, 1) Dapagliflozin, (3) Description of specific adverse reactions, ⑦ Perineal gangrene (Fournier gangrene)]. Perineal gangrene has been reported in both men and women, resulting in hospitalization, multiple surgeries, and death.
If a patient receiving dapagliflozin develops pain, soreness, erythema, or swelling around the genitals or perineum along with fever and discomfort, perineal gangrene should be checked. If perineal gangrene is suspected, broad-spectrum antibiotic treatment should be started immediately and surgical resection should be performed if necessary. Administration of dapagliflozin should be discontinued, blood sugar levels should be closely monitored, and appropriate alternative treatment should be implemented to control blood sugar.
12) Severe and disabling joint pain
Severe and disabling arthralgia have been reported in post-marketing studies in patients taking DPP-4 inhibitors. The onset of symptoms after drug administration varied from 1 day to several years later. Symptoms were alleviated when drug administration was stopped. In some patients, recurrence of symptoms occurred when taking the same drug or a different DPP-4 inhibitor. Consider the DPP-4 inhibitor as the cause of severe arthralgia and, if appropriate, discontinue administration.
13) Bullous pemphigoid
In post-marketing surveillance in patients taking DPP-4 inhibitors, cases of bullous pemphigus requiring hospitalization have been reported. Patients generally recovered with discontinuation of DPP-4 inhibitors and treatment with topical or systemic immunosuppressants. Patients should be informed to immediately report to their doctor if blisters or sores occur while taking sitagliptin. If bullous pemphigus is suspected, sitagliptin should be discontinued and the patient should be referred to a dermatologist for diagnosis and appropriate treatment.
14) Hypoxic state: Cardiovascular collapse (shock) of any cause, acute congestive heart failure, acute myocardial infarction and other conditions characterized by hypoxia are associated with lactic acidosis and may cause prerenal azotemia. If this occurs in a patient receiving treatment with this drug, administration of this drug should be discontinued immediately.
15) Cardiac function: Patients with heart failure have a higher risk of hypoxia and decreased renal function. For patients with stable chronic heart failure, metformin can be administered with regular monitoring of heart and kidney function.
16) Alcohol intake: Alcohol is known to increase the effect of metformin on lactic acid metabolism. Therefore, acute or chronic excessive intake of alcohol should be avoided while taking this medicine.
17) Vitamin B12 levels: It is recommended to monitor serum vitamin B12 levels annually. The risk of low vitamin B12 levels increases in patients with higher metformin doses, longer treatment duration, and/or with risk factors known to cause vitamin B12 deficiency.
18) Hypoglycemia: Hypoglycemia does not occur in patients who take metformin alone under normal use circumstances, but occurs when caloric intake is insufficient, when vigorous exercise is not supplemented by caloric intake, or when other hypoglycemic agents (sulfonylurea, insulin, meglitinide, etc.) or alcohol are administered concurrently. Hypoglycemia is especially likely to occur in the elderly, weak or malnourished patients, patients with adrenal or pituitary insufficiency, or alcoholics. Hypoglycemia may be difficult to identify in older adults and people taking β-adrenergic blocking drugs. When symptoms of hypoglycemia are recognized due to administration of metformin, sugar (sucrose) is generally administered, and when symptoms of hypoglycemia are recognized due to concurrent use with an α-glucosidase inhibitor (acarbose, voglibose), glucose is administered.
19) Gastrointestinal disorders
When administering metformin, gastrointestinal disorders such as nausea, vomiting, diarrhea, abdominal pain, and anorexia occur most frequently in the early stages of treatment and disappear spontaneously in most cases. Gradually increasing the dose may help increase gastrointestinal tolerability. Since gastrointestinal symptoms occur in a dose-related manner during the initial stage of treatment, they can be reduced by gradually increasing the dose or administering metformin with meals. Severe diarrhea and/or vomiting may cause dehydration and prerenal azotemia and should be temporarily discontinued under these conditions. In patients stabilized on metformin, non-specific gastrointestinal symptoms may not be due to treatment but may be due to concurrent disease or lactic acidosis.
20) Changes in controlled diabetic patients: If abnormal laboratory findings or clinical disease (especially vague and poorly defined disease) occurs in a patient whose type 2 diabetes was previously well controlled with this drug, the patient should be immediately evaluated for the development of ketoacidosis or lactic acidosis. Serum electrolytes, ketones, and blood sugar are tested, and, if necessary, blood pH, lactate, pyruvate, and metformin levels. If any form of acidosis appears, immediately discontinue metformin administration and take other appropriate and correct measures.
21) Co-administration with drugs that may affect renal function or metformin metabolism or excretion: Co-administration with drugs that may affect renal function, cause significant hemodynamic changes, or inhibit the metabolism or excretion of metformin, such as cationic drugs excreted through renal tubular discharge, should be used with caution (see Section 6. Interactions).
22) Patients with specific occupations: In rare cases, severe lactic acidosis and severe delayed hypoglycemia may occur, so caution should be exercised when administering to patients engaged in work at heights or driving a car. In addition, provide sufficient and thorough warning to patients and their families regarding lactic acidosis and hypoglycemia.
23) This medicine should be swallowed whole rather than crushed or chewed. Patients should be informed in advance that this is normal as the tablet shell may pass through the stool.
6. Interaction
1) Dapagliflozin
(1) Pharmacodynamic interaction
① Diuretics: Dapagliflozin may increase the diuretic effect of thiazides and loop diuretics and may increase the risk of dehydration and hypotension.
② Insulin and insulin secretion stimulants: Insulin secretion stimulants such as insulin and sulfonylureas can cause hypoglycemia. Therefore, to reduce the risk of hypoglycemia when administered in combination with dapagliflozin, the dose of insulin or insulin secretagogue may need to be reduced.
(2) Pharmacokinetic interactions
① The metabolism of dapagliflozin is mainly accomplished through glucuronide conjugation mediated by UDP-glucuronidase 1A9 (UGT1A9).
② In laboratory (in-vitro) studies, dapagliflozin did not inhibit cytochrome P450 (CYP) 1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A4, or induce CYP1A2, CYP2B6, or CYP3A4. Therefore, dapagliflozin is not expected to alter the metabolic excretion of drugs metabolized by these enzymes when coadministered with these drugs.
(3) Effects of other medicines on dapagliflozin
① As a result of an interaction study conducted on healthy subjects mainly using a single-dose design, the pharmacokinetics of dapagliflozin were not changed by metformin, pioglitazone, sitagliptin, glimepiride, voglibose, hydrochlorothiazide, bumetanide, valsartan, or simvastatin.
② After co-administering dapagliflozin with rifampicin (an inducer of various active transporters and drug-metabolizing enzymes), a 22% decrease in dapagliflozin systemic exposure (AUC) was observed, but there was no clinically significant effect on 24-hour urinary glucose excretion. Dosage adjustments are not recommended. Clinically relevant effects are not expected with other inducers (e.g., carbamazepine, phenytoin, phenobarbital).
③ After co-administering dapagliflozin with mefenamic acid (an inhibitor of UGT1A9), systemic exposure to dapagliflozin increased by 55%, but there was no clinically significant effect on 24-hour urinary glucose excretion. Dosage adjustments are not recommended.
(4) Effect of dapagliflozin on other medicines
Dapagliflozin may increase renal excretion of lithium and decrease blood lithium concentrations. Serum lithium concentrations should be monitored more frequently upon initiation of dapagliflozin and after dose changes. Refer the patient to the doctor who prescribed lithium to monitor serum lithium levels.
In interaction studies conducted in healthy subjects, primarily using a single-dose design, dapagliflozin had an anticoagulant effect on the pharmacokinetics of metformin, pioglitazone, sitagliptin, glimepiride, hydrochlorothiazide, bumetanide, valsartan, digoxin (a P-gp substrate), or warfarin (S-warfarin, a CYP2C9 substrate), or the anticoagulant activity of warfarin as assessed by INR. didn't change A single co-administration of dapagliflozin 20 mg and simvastatin (CYP3A4 substrate) resulted in a 19% increase in simvastatin AUC and a 31% increase in simvastatin acid AUC. Elevated simvastatin and simvastatin acid exposure are not considered clinically relevant.
(5) Other interactions
The effects of smoking, diet, herbal medicines and alcohol on the pharmacokinetics of dapagliflozin have not been studied.
(6) Pediatrics
Interaction studies were conducted only in adults.
(7) Interference with 1,5-anhydroglucitol test
The 1,5-anhydroglucitol test is not recommended as a blood sugar control monitoring test in patients taking SGLT2 inhibitors because the reliability of the measurement results is low. Different methods are used to monitor blood sugar control.
2) Sitagliptin
In drug interaction studies, sitagliptin did not have a clinically significant effect on the pharmacokinetics of the following drugs: metformin, rosiglitazone, glibenclamide, simvastatin, warfarin, and oral contraceptives. Based on this test, it is not expected to act on substrates of CYP3A4, CYP2C8, CYP2C9 and organic cation transporters.
Co-administration of metformin and sitagliptin taken twice daily in patients with type 2 diabetes does not significantly change the pharmacokinetics of sitagliptin.
Cyclosporine: When administered as a single dose in combination with 600 mg of cyclosporine, a strong p-glycoprotein inhibitor, the AUC (29%) and Cmax (68%) of sitagliptin were increased, but the change in the pharmacokinetics of sitagliptin is not expected to be clinically significant. No significant interaction is expected when coadministered with cyclosporine or other p-glycoprotein inhibitors.
Digoxin: When coadministered with 100 mg of sitagliptin for 10 days, the plasma AUC (11%) and Cmax (18%) of digoxin increased slightly. Appropriate monitoring should be conducted when administering digoxin, and dose adjustment of sitagliptin and digoxin is not necessary.
3) Metformin
(1) Since the blood sugar-lowering effect may be enhanced or decreased by combined use with the following drugs, when used together, administer while carefully observing the blood sugar level and the condition of other patients.
- Drugs that increase blood sugar lowering action
Insulin preparations, sulfonylamide and sulfonylurea drugs, meglitinides (repaglinide, etc.), β-blockers (propranolol, etc.), MAO inhibitors, alpha-glycosidase inhibitors (alkalophos), anabolic steroids, guanethidine, salicylates (aspirin, etc.),
- Drugs that reduce blood sugar lowering action
Epinephrine, sympathomimetics, corticosteroids, thyroid hormones, follicular hormones, estrogens, oral contraceptives, thiazide and other diuretics, pyrazinamide, isoniazid, nicotinic acid, phenothiazines, phenytoin, calcium channel antagonists.
(2) Alcohol: The risk of lactic acidosis increases during the acute alcohol intoxication period, especially in the following circumstances.
- Hungry or malnutrition
- Liver dysfunction
You should avoid drinking alcohol and taking drugs that contain alcohol.
(3) Iodine-labeled contrast media: Renal failure may occur in association with intravenous administration of iodine-labeled contrast media, which may cause metformin accumulation and may expose patients to the risk of lactic acidosis. Metformin should be discontinued before or at the time of testing with iodine-labeled contrast media, and treatment should be resumed only after at least 48 hours and after reassessment of renal function and determination that there is no risk of further damage. (Refer to 2. Do not administer to the following patients.)
(4) Glyburide: In a single-dose study on patients with type 2 diabetes, co-administration of metformin and glyburide did not cause changes in the pharmacokinetics or pharmacodynamic properties of metformin. A decrease in the AUC and Cmax of glyburide was observed, but the deviation was large. The lack of correlation between blood concentrations and pharmacokinetic effects of metformin after a single dose in this study indicates that the clinical significance of this interaction is unclear.
(5) Furosemide: A study on the drug interaction of metformin and furosemide administered as a single dose in healthy people showed that the pharmacokinetic values of each substance were affected by co-administration. Furosemide increases the plasma concentration of metformin without significant changes in the renal clearance of metformin, and increases blood Cmax by 22% and blood AUC by 15%. When co-administered with metformin, the Cmax and AUC of furosemide are reduced by 31% and 12%, respectively, compared to single administration, and the terminal half-life of furosemide is reduced by 32% without changing the renal clearance of furosemide. There is no available information regarding the interaction when metformin and furosemide are co-administered chronically.
(6) Nifedipine: A study on the drug interaction between metformin and nifedipine in a single dose in normal healthy volunteers showed that co-administration with nifedipine increases the Cmax and AUC of metformin in plasma by 20% and 9%, respectively, and increases urinary excretion. Tmax and half-life are not affected. Nifedipine promotes the absorption of metformin. Metformin does not significantly affect nifedipine.
(7) Drugs that may affect metformin, such as cationic drugs that may affect renal function, cause significant hemodynamic changes, or are excreted through renal tubular secretion: Metformin is a substrate of the organic cation transporter (OCT) OCT1 and OCT2.
- When used in combination with OCT1 inhibitors (verapamil, etc.), the efficacy of metformin may be reduced.
- When used in combination with OCT1 inducers (rifampicin, etc.), the gastrointestinal absorption and efficacy of metformin may increase.
- When used in combination with OCT2 inhibitors (cimetidine, dolutegravir, ranolazine, trimethoprim, vandetanib, isavuconazole, etc.), the renal excretion of metformin may be reduced and the blood concentration of metformin may increase.
- When used in combination with OCT2 and OCT1 simultaneous inhibitors (crizotinib, olaparib), the renal excretion and efficacy of metformin may be affected.
Therefore, when metformin and these drugs are administered together, the blood concentration of metformin may increase, so caution is needed, especially in patients with renal impairment. Because OCT inhibitors/inducers may change the efficacy of metformin, dose adjustment of metformin may be considered if necessary.
In addition, nonsteroidal anti-inflammatory drugs (NSAIDs), including selective COX-II (Cyclo-oxygenase) inhibitors, angiotensin-converting enzyme inhibitors (ACE inhibitors), angiotensin II receptor antagonists, and diuretics (especially loop diuretics) may have an adverse effect on renal function and increase the risk of lactic acidosis. Therefore, renal function should be carefully monitored when administered in combination with metformin. Must observe.
(8) Others: In single-dose co-administration studies in healthy volunteers, the pharmacokinetic properties of metformin and propranolol and metformin and ibuprofen were not affected by each other.
Metformin's binding to plasma proteins is negligible, so compared to sulfonylureas, which are extensively bound to plasma proteins, it has little interaction with drugs that are heavily bound to proteins, such as salicylates, sulfonamides, chloramphenicol, and probenecid.
7. Administration to pregnant and lactating women
There are no appropriate clinical trial results for this drug in pregnant and lactating women, so use of this drug during pregnancy or lactation is not recommended.
Information on the individual ingredients is as follows.
1) Pregnant women:
(1) Dapagliflozin: There is no data on the administration of dapagliflozin to pregnant women. Studies on rats showed toxicity to kidney development during the second and third trimesters of human pregnancy. The use of dapagliflozin in pregnant women is not recommended. Once pregnancy is confirmed, dapagliflozin administration should be discontinued.
The effects of dapagliflozin on human fertility have not been studied. In male and female rats, dapagliflozin showed no effects on fertility at any of the doses studied.
(2) Sitagliptin: There are no controlled test results in pregnant women, so its use in pregnant women is not recommended.
(3) Metformin: Uncontrolled hyperglycemia during the periconceptional phase and pregnancy is associated with an increased risk of congenital abnormalities, miscarriage, pregnancy-induced hypertension, preeclampsia, and perinatal mortality. It is important to keep blood sugar levels as close to normal as possible throughout pregnancy to reduce the risks associated with high blood sugar during pregnancy.
Metformin crosses the placenta, and levels of transplacental passage can be as high as maternal concentrations.
Based on data (>1000 exposures) from various studies (clinical studies, register-based cohort studies, meta-analyses, etc.) on metformin use in the periconceptional phase and during pregnancy, no increased risk of congenital abnormalities and/or fetal/neonatal toxicity due to metformin exposure during the periconceptional phase and/or pregnancy has been identified.
Babies exposed to metformin in utero may be small for gestational age. There is limited evidence on the effects of metformin on long-term birth weight outcomes and metabolic complications in infants. It does not appear to affect motor-social development up to 4 years of age, but results beyond 4 years of age are limited.
If you are planning to become pregnant or are clinically necessary for the purpose of controlling blood sugar levels during pregnancy, the use of metformin may be considered in addition to or as an alternative to insulin.
However, pregnant women at risk for placental insufficiency, preeclampsia, or intrauterine growth retardation should not begin treatment with metformin. Fetal development should be closely monitored to prevent birth weight loss, and metformin administration should be discontinued if fetal growth retardation is confirmed.
2) Nursing mothers
(1) Dapagliflozin: It is not known whether dapagliflozin and its metabolites are transferred into human milk. Pharmacodynamic/toxicological data in animals indicate excretion of dapagliflozin/metabolite in milk and pharmacologically mediated effects in nursing offspring. Risk to neonates/infants cannot be excluded. Dapagliflozin should not be used during breastfeeding.
(2) Sitagliptin: Sitagliptin is reported to be secreted into milk and plasma at a ratio of 4:1 in rats, so it is not administered to nursing mothers.
(3) Metformin: Metformin is secreted into breast milk, and no adverse reactions to metformin have been reported in newborns/infants. However, because reported study results are limited, breastfeeding during treatment with metformin is not recommended. Considering the benefits of breastfeeding, the importance of the drug to the nursing mother, and the potential risk of adverse reactions in the infant, a decision should be made whether to discontinue breastfeeding or drug treatment.
8. Administration to children
Safety and efficacy in pediatric patients under 18 years of age have not been established.
9. Administration to elderly people
Elderly people generally have decreased physiological functions, such as liver and kidney function, due to aging, and are likely to be taking drugs that are likely to cause changes in renal function (e.g., antihypertensive drugs that can cause changes in renal function, such as angiotensin-converting enzyme inhibitors (ACE-I) and angiotensin II receptor inhibitors (ARB)). Elderly patients may be at higher risk for volume loss and are more likely to be taking diuretics. When administering this drug to the elderly, dosage adjustment may be necessary based on renal function, and the patient's condition should be observed and administered with caution.
Among these drugs, sitagliptin is mostly excreted through the kidneys, so caution is required when selecting the dosage in elderly patients. The dose of metformin should be set to the minimum dose that can achieve appropriate blood sugar control effects based on the patient's renal function (refer to the section on patients with renal impairment in Dosage and Administration), and the maximum dose is generally not administered to the elderly.
It is recommended to evaluate renal function and body fluid status before and after administration of this drug in elderly patients.
10. Treatment in case of overdose
1) Dapagliflozin
Dapagliflozin did not show any toxicity at single oral doses of up to 500 mg (50 times the maximum recommended human dose) in healthy subjects. These subjects had detectable urinary glucose throughout the treatment period (more than 5 days for the 500 mg dose), no dehydration, hypotension, or electrolyte imbalances were reported, and there were no clinically significant effects on the QTc interval. The incidence of hypoglycemia was similar to placebo. In a clinical trial in which healthy subjects and patients with type 2 diabetes were administered up to 100 mg once daily for 2 weeks (10 times the maximum recommended human dose), the incidence of hypoglycemia was slightly higher than in the placebo group and was not dose-related. Rates of adverse events, including dehydration or hypotension, were similar to the placebo group, and there were no clinically meaningful dose-related changes in laboratory parameters, including serum electrolytes and biomarkers of renal function.
If overdose occurs, appropriate symptomatic treatment should be administered according to the patient's clinical condition. Elimination of dapagliflozin by dialysis has not been studied.
2) Sitagliptin
In clinical trials of sitagliptin, a single dose of up to 800 mg of sitagliptin was administered to healthy adults. In one study administering 800 mg of sitagliptin, an increase in mean QTc of up to 8.0 msec was observed, but this is not believed to be clinically relevant. There is no experience administering doses exceeding 800 mg in humans.
In case of overdose, general symptomatic treatment is administered (e.g., removal of unabsorbed drug from the gastrointestinal tract and clinical monitoring including electrocardiogram), and auxiliary treatment is provided depending on the patient's condition.
Sitagliptin can be partially removed by dialysis. In clinical trials, approximately 13.5% of the administered dose was removed during hemodialysis over 3 to 4 hours. Long-term hemodialysis should be considered if clinically appropriate. It is not known whether sitagliptin is removed by peritoneal dialysis.
3) Metformin
Even if metformin hydrochloride is administered up to 85g, hypoglycemia does not occur even if lactic acidosis occurs in this condition. Metformin is dialyzed with clearance rates reaching 170 mL/min under favorable hemodynamic conditions. Therefore, hemodialysis may be useful to remove accumulated drug in patients suspected of overdosing on metformin.
11. Storage and handling precautions
1) Store out of reach of children.
2) It is not advisable to change the container as it may damage the quality of the product or cause an accident. Store in original container.
12. Information for professionals
*Refer to attached document
5. How to save
Airtight container, stored at room temperature (1~30℃)
6. Packaging unit
30 tablets/bottle
7. Period of use
30 months from date of manufacture
- Active ingredients:
Dapagliflozin propanediol hydrate (in-house specification) · · · · · · · 12.3mg (10mg as dapagliflozin)
Sitagliptin hydrochloride hydrate (in-house specification) · · · · · · · · 113.4mg (100mg as sitagliptin)
Metformin hydrochloride (BP) · · · · · · · · 1000mg
- Additives: Anhydrous calcium hydrogen phosphate, microcrystalline cellulose, magnesium stearate, Opadry yellow (85F12372), sodium carboxymethyl cellulose, colloidal silicon oxide, croscarmellose sodium, hydroxypropyl cellulose, hypromellose
2. Effectiveness
This drug is administered as an adjunct to diet and exercise therapy to improve glycemic control in patients with type 2 diabetes who are suitable for combined administration of dapagliflozin, sitagliptin, and metformin.
3. Dosage and dosage
In anti-diabetic therapy, the recommended dose of this drug is 10 mg for dapagliflozin and 100 mg for sitagliptin, and the dosage for extended-release metformin hydrochloride is determined in consideration of each patient's current treatment regimen, effectiveness, and tolerability in a range not exceeding 2000 mg.
This drug is taken once a day in the evening with a meal to reduce adverse gastrointestinal reactions caused by metformin hydrochloride. If the dose of metformin hydrochloride needs to be adjusted, adjust the dose step by step.
Patients taking this 10/100/1000 mg sustained-release tablet should take one tablet once a day.
Patients taking this drug and 5/50/1000 mg sustained-release tablets should take 2 tablets once a day simultaneously. If sufficient blood sugar control cannot be achieved with the combination therapy of metformin hydrochloride and sitagliptin, administer dapagliflozin 10 mg sitagliptin 100 mg as the starting dose of this drug and the dose of metformin hydrochloride being taken or a dose therapeutically close to it.
For patients switching from dapagliflozin, sitagliptin, and metformin hydrochloride combination therapy to this drug, the dose of this drug is the existing dose of each component.
The safety and effectiveness of this drug have not been specifically evaluated in patients switching to this drug from other hypoglycemic agents. Any changes in the treatment of patients with type 2 diabetes should be made under careful monitoring because they may cause changes in glycemic control.
To maintain its sustained-release properties, this medication should be swallowed without breaking, crushing, grinding, or chewing. This medication may be incompletely dissolved and excreted in the feces. It is not known whether the substance excreted in feces contains the active ingredient of the drug. If the patient repeatedly reports that this drug has been found in the stool, the healthcare provider should evaluate whether blood sugar is adequately controlled (see Precautions for Use, Section 5. General Precautions).
special group
Patients with renal impairment
Since the effectiveness and safety of this drug depend on renal function and dose adjustment is necessary depending on renal function, it is recommended to periodically evaluate renal function before and after administration of this drug.
No dose adjustment is necessary for patients with mild renal impairment.
In patients with an estimated glomerular filtration rate (eGFR) of 45 mL/min/1.73 m2 or more but less than 60 mL/min/1.73 m2, if the drug is well tolerated and does not have other symptoms that may increase the risk of lactic acidosis, it can be used by adjusting the dose of metformin hydrochloride, one of the components of this drug. The starting dose of sustained-release metformin hydrochloride is 500 mg or 750 mg once a day, so treatment with this drug should not be started. The maximum daily dose of metformin hydrochloride is 1000 mg.
If the estimated glomerular filtration rate (eGFR) falls below 45 mL/min/1.73 m2, administration of this drug should be discontinued immediately. Renal function should be assessed every 3 to 6 months.
4. Precautions for use
1. Warning
1) Sitagliptin
(1) Hypersensitivity reaction
Severe hypersensitivity reactions have been reported in patients receiving post-marketing sitagliptin, including anaphylaxis, angioedema, and exfoliative skin disorders, including Stevens-Johnson syndrome. Because they are voluntarily reported from an unspecified population, it is generally not possible to reliably estimate their incidence or establish a causal relationship with drug exposure. The onset of this reaction occurred within the first 3 months of drug treatment and has also been reported after the first dose. If hypersensitivity reaction is suspected, discontinue this drug, evaluate other potential reasons for the occurrence, and implement other diabetes treatment (see 2. Do not administer to the following patients and 4. Adverse reactions, 2) Sitagliptin, (2) Post-marketing adverse reactions).
(2) Pancreatitis
Acute pancreatitis, including fatal/non-fatal hemorrhagic or necrotizing pancreatitis, has been reported in patients treated with sitagliptin (see section 4. Adverse reactions, 2) Sitagliptin). After starting treatment with this drug, carefully observe whether symptoms of pancreatitis appear. If pancreatitis is suspected, administration of this drug and other suspected drugs should be discontinued.
2) Metformin
(1) In rare cases, severe lactic acidosis or hypoglycemia may occur. Cases of death due to lactic acidosis have been reported.
2. Do not administer to the following patients
1) Patients with known hypersensitivity to this drug or its ingredients
2) Patients with moderate (stage3b) or higher renal impairment (creatinine clearance <45mL/min or glomerular filtration rate <45mL/min/1.73m2), acute conditions that may affect renal function such as dehydration, serious infection, cardiovascular collapse (shock), acute myocardial infarction, and sepsis.
3) Patients with acute and unstable heart failure
4) Patients undergoing tests that involve intravenous administration of radioiodine contrast material (e.g. intravenous urography, intravenous cholangiography, angiography, computed tomography using contrast media, etc.) (can cause acute renal failure, and are associated with lactic acidosis in patients receiving this drug. Therefore, among patients scheduled for such tests, if the glomerular filtration rate is >60ml/min/1.73m2, at least at the time of the test or in advance The drug must be discontinued, and re-administration is not possible within 48 hours. In patients with moderate renal impairment (glomerular filtration rate 45-60 ml/min/1.73 m2), re-administration is not possible within 48 hours after renal function is re-evaluated. Treatment is resumed only after this.)
5) Patients with acute or chronic metabolic acidosis, including type 1 diabetes, lactic acidosis, diabetic ketoacidosis with or without coma, and patients with a history of ketoacidosis [Type 1 diabetes and diabetic ketoacidosis are treated with insulin.]
6) Diabetic precoma
7) In patients with severe infections or severe traumatic systemic disorders, treatment with this drug should be temporarily stopped and treatment should be restarted when the patient's oral intake is restored and renal function is found to be normal.
8) In the case of surgical procedures (excluding minor surgeries where there are no restrictions on food and fluid intake), this drug should be temporarily stopped 48 hours before surgery, and treatment should be restarted at least 48 hours after renal function is confirmed to be normal.
9) Patients with malnutrition, starvation, weakness, pituitary dysfunction, or adrenal dysfunction
10) Impaired liver function (since impaired liver function is associated with some cases of lactic acidosis, administration of this drug should generally be avoided in patients with clinical or laboratory evidence of liver disease), acute or chronic diseases that may cause tissue hypoxia such as respiratory failure, acute myocardial infarction, and shock, excessive alcohol intake, and patients with gastrointestinal disorders such as dehydration, diarrhea, and vomiting.
11) Pregnant women at risk of placental insufficiency, preeclampsia, and intrauterine growth retardation (see section 7. Administration for pregnant and lactating women)
3. Administer with caution to the following patients:
1) Administration in patients with decreased body volume and renal dysfunction
Dapagliflozin may cause a decrease in intravascular blood volume, which may manifest as symptomatic hypotension or sudden and temporary changes in creatinine. In foreign post-marketing surveillance, acute kidney injury was reported in patients receiving SGLT-2 inhibitors, including dapagliflozin, and some required hospitalization and dialysis. The risk of decreased blood volume or hypotension may increase in patients with renal dysfunction (eGFR less than 60mL/min/1.73m2?), the elderly, and those using loop diuretics. For patients with these characteristics, it is necessary to evaluate body fluid status and renal function before starting dapagliflozin administration, and after starting administration, monitor symptoms and signs of hypotension and renal function.
The glucose-lowering efficacy of dapagliflozin depends on renal function. Efficacy is reduced in patients with moderate renal impairment, and dapagliflozin is not recommended solely for glycemic control in patients with type 2 diabetes and an eGFR below 45 mL/min/1.73 m². Among patients with moderate renal impairment, elevated creatinine, phosphorus and parathyroid hormone (PTH) levels and hypotension were reported more frequently with dapagliflozin than with placebo.
Sitagliptin is excreted by the kidneys. In order to reach blood levels similar to those in patients with normal renal function, low doses are recommended in patients with a glomerular filtration rate [eGFR] <45 mL/min/1.73 m2 and in patients with end-stage renal disease (ESRD) requiring hemodialysis or peritoneal dialysis, so this drug is not administered.
Metformin is excreted by the kidneys, and the risk of metformin accumulation and lactic acidosis increases with the degree of renal dysfunction. Therefore, patients with serum creatinine levels above the upper limit of normal for their age should not take this drug.
2) The following patients or conditions (there is a possibility of lactic acidosis and hypoglycemia)
(1) Irregular meal intake, insufficient meal intake
(2) Intense muscle exercise
(3) Patients taking interacting drugs
4. Adverse reactions
1) Dapagliflozin
(1) Summary of safety profile
In clinical studies of patients with type 2 diabetes, more than 15,000 patients received dapagliflozin.
Safety and tolerability were assessed through a predefined pooled analysis of 13 short-term (up to 24 weeks) placebo-controlled trials involving 2,360 patients administered 10 mg of dapagliflozin and 2,295 patients administered placebo.
In the clinical trial to evaluate the cardiovascular effects of dapagliflozin in patients with type 2 diabetes (DECLARE), 8,574 people were administered dapagliflozin 10 mg and 8,569 people were administered placebo, and the median exposure period was 48 months. There were a total of 30,623 patient-years of dapagliflozin exposure.
The most commonly reported adverse reactions throughout clinical studies were genital infections.
(2) List of adverse reactions
The following adverse reactions were observed in placebo-controlled clinical trials. There were no dose-related adverse reactions. The adverse reactions listed below are classified according to frequency and organ system (SOC). Frequency of presentation was defined as follows: very common (≥ 1/10), common (≥ 1/100 to <1/10), uncommon (≥ 1/1,000 to <1/100), rare (≥ 1/10,000 to <1/1,000), very rare (< 1/10,000), and unknown (cannot be assessed from available data).
*Table 1: Refer to attached document
(3) Description of specific adverse reactions
① Vulvovaginitis, balanitis and related genital infections
Pooled safety data from 13 clinical trials showed that vulvovaginitis, balanitis, and related genital infections were reported in 5.5% and 0.6% of subjects receiving dapagliflozin 10 mg and placebo, respectively. Most infections were mild to moderate, subjects responded to initial standard treatment, and rarely led to discontinuation of dapagliflozin. These infections were more common in women (8.4% and 1.2% in the dapagliflozin and placebo groups, respectively), and subjects with a prior medical history were more likely to have recurrent infections.
In the DECLARE clinical trial, the number of serious adverse events of genital infection was very small and evenly distributed (2 patients each in the dapagliflozin and placebo groups).
In the DAPA-HF clinical trial, no serious adverse events of genital infection were reported in the dapagliflozin group and one case was reported in the placebo group. There were 7 patients (0.3%) in the dapagliflozin group and none in the placebo group who discontinued treatment due to adverse events of genital infection.
In the DAPA-CKD clinical trial, serious adverse events of genital infection were reported in 3 cases (0.1%) in the dapagliflozin group and none in the placebo group. There were 3 patients (0.1%) in the dapagliflozin group and none in the placebo group who discontinued treatment due to adverse events of genital infection. In patients without diabetes, no serious adverse events of genital infection or adverse events leading to discontinuation of treatment were reported.
② Low blood sugar
The frequency of hypoglycemia in clinical trials in patients with diabetes depended on the type of baseline therapy used in each trial.
In additional combination studies of dapagliflozin alone, metformin, or sitagliptin (metformin alone or in combination), the frequency of mild hypoglycemic episodes was similar (<5%) between treatment groups, including placebo, up to 102 weeks of treatment. In a comprehensive analysis of safety information from 1,169 patients evaluated for dapagliflozin and saxagliptin combination therapy, the overall incidence of hypoglycemia was low at 24 weeks (≤1.8% in all groups).
In all trials, major hypoglycemic events were uncommon and equivalent between dapagliflozin and placebo groups. The incidence of hypoglycemia was higher in studies with the addition of sulfonylurea and in studies with the addition of insulin.
In the glimepiride add-on study, mild hypoglycemic episodes were reported more frequently at weeks 24 and 48 in those receiving dapagliflozin 10 mg and glimepiride (6.0% and 7.9%, respectively) compared to those receiving placebo and glimepiride (2.1% and 2.1%, respectively).
In the insulin add-on combination study, major hypoglycemic episodes were reported in 0.5% and 1.0% of patients at weeks 24 and 104, respectively, in patients administered dapagliflozin 10 mg in combination with insulin, and 0.5% were reported at weeks 24 and 104 in patients administered placebo in combination with insulin. Minor hypoglycemic episodes were reported in patients administered dapagliflozin 10 mg in combination with insulin. It was reported in 40.3% and 53.1% at weeks 24 and 104, respectively, and in patients receiving placebo with additional insulin, it was reported in 34.0% and 41.6%.
In an add-on therapy trial of metformin and sulfonylureas, no major episodes of hypoglycemia were reported by week 24. Mild hypoglycemic episodes were reported in 12.8% of subjects receiving dapagliflozin 10 mg plus metformin and sulfonylurea and in 3.7% of subjects receiving placebo plus metformin and sulfonylurea.
The DECLARE trial showed that dapagliflozin therapy compared with placebo did not increase the risk of major hypoglycemic events. Major hypoglycemic events were reported in 58 patients (0.7%) in the dapagliflozin group and in 83 patients (1.0%) in the placebo group.
In the DAPA-HF clinical trial, major hypoglycemic events were reported in 4 patients (0.2%) each in the dapagliflozin and placebo groups, and occurred only in patients with type 2 diabetes.
In the DAPA-CKD clinical trial, major hypoglycemic events were reported in 14 patients (0.7%) in the dapagliflozin group and 28 patients (1.3%) in the placebo group, and were observed only in patients with type 2 diabetes.
③ Reduction in body fluid volume
According to pooled safety data from 13 clinical trials, drug reactions suggestive of volume loss (including dehydration, hypovolemia, or hypotension) were reported in 1.1% and 0.7% of subjects receiving dapagliflozin 10 mg and placebo, respectively; Serious reactions, occurring in less than 0.2% of subjects, were evenly distributed between the dapagliflozin 10 mg and placebo groups.
In the DECLARE clinical trial, the number of patients who developed adverse events suggesting a decrease in body fluid volume was evenly distributed among treatment groups: 213 (2.5%) in the dapagliflozin group and 207 (2.4%) in the placebo group. Serious adverse events were reported in 81 patients (0.9%) in the dapagliflozin group and 70 patients (0.8%) in the placebo group. Adverse events were generally evenly distributed between treatment groups across subgroups, including age, use of diuretics, blood pressure, and use of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers. In the patient population with a baseline estimated glomerular filtration rate (eGFR) of less than 60 mL/min/1.73 m2?, 19 serious adverse events suggesting decreased body fluid volume were reported in 19 cases in the dapagliflozin group and 13 cases in the placebo group.
In the DAPA-HF clinical trial, the number of patients with adverse events suggesting a decrease in body fluid volume was 170 (7.2%) in the dapagliflozin group and 153 (6.5%) in the placebo group. The number of patients with serious adverse events suggesting volume loss was lower in the dapagliflozin group (23 patients [1.0%]) than in the placebo group (38 patients [1.6%]). Similar results were observed across subgroups including age, presence of diabetes at baseline, baseline eGFR, and systolic blood pressure.
In the DAPA-CKD clinical trial, the number of patients with adverse events suggesting a decrease in body fluid volume was 120 (5.6%) in the dapagliflozin group and 84 (3.9%) in the placebo group. The number of patients with serious adverse events suggesting a decrease in body fluid volume was 16 (0.7%) in the dapagliflozin group and 15 (0.7%) in the placebo group.
④ Diabetic ketoacidosis
In the DECLARE clinical trial (median dapagliflozin exposure period of 48 months), 27 cases of diabetic ketoacidosis were reported in the patient group administered dapagliflozin 10 mg and 12 cases in the placebo group. Occurrence points were evenly distributed throughout the study period. Of the 27 patients who developed diabetic ketoacidosis in the dapagliflozin group, 22 were taking insulin at the time the case occurred. Precipitating factors for diabetic ketoacidosis appeared as expected in the type 2 diabetes patient population (see sections 5. General precautions, 5) Ketoacidosis).
In the DAPA-HF clinical trial, diabetic ketoacidosis cases were reported in 3 patients with type 2 diabetes in the dapagliflozin group and no cases in the placebo group.
In the DAPA-CKD clinical trial, no cases of diabetic ketoacidosis were reported in the dapagliflozin group and two cases of type 2 diabetes were reported in the placebo group.
⑤ Urinary tract infection
Pooled safety data from 13 clinical trials showed that urinary tract infections were reported more frequently in the dapagliflozin 10 mg group compared to the placebo group (4.7% vs 3.5%, respectively). Most infections were mild to moderate, subjects responded to initial standard treatment, and rarely led to discontinuation of dapagliflozin. These infections were more common in women, and subjects with a previous medical history were more likely to develop recurrent infections.
In the DECLARE clinical trial, 79 cases (0.9%) of serious adverse events of urinary tract infection were reported in the dapagliflozin 10 mg treatment group, which was less frequent than the 109 cases (1.3%) in the placebo group.
In the DAPA-HF clinical trial, the number of patients who experienced serious adverse events of urinary tract infection was small, with no significant difference between the two groups: 14 patients (0.6%) in the dapagliflozin group and 17 patients (0.7%) in the placebo group. There were 5 patients (0.2%) in each of the dapagliflozin and placebo groups who discontinued treatment due to adverse events of urinary tract infection.
In the DAPA-CKD clinical trial, the number of patients who experienced serious adverse events of urinary tract infection was 29 (1.3%) in the dapagliflozin group and 18 (0.8%) in the placebo group. There were 8 patients (0.4%) in the dapagliflozin group and 3 (0.1%) in the placebo group who discontinued treatment due to adverse events of urinary tract infection.
⑥ Increased creatinine
Adverse reactions associated with increased creatinine were classified as decreased renal creatinine clearance, renal impairment, increased blood creatinine, and decreased glomerular filtration rate. According to pooled safety data from 13 clinical trials, these adverse reactions were reported in 3.2% and 1.8% of subjects receiving dapagliflozin 10 mg and placebo, respectively. In normal subjects or patients with mild renal failure (eGFR 60 mL/min/1.73 m2? or higher), these adverse reactions were reported in 1.3% and 0.8% of patients receiving dapagliflozin 10 mg and placebo, respectively. These adverse reactions were reported more frequently in patients with an eGFR greater than 30 mL/min/1.73 m2? or less than 60 mL/min/1.73 m2? (18.5% and 9.3% with dapagliflozin 10 mg and placebo, respectively).
In the subsequent evaluation of patients with kidney-related adverse events, changes in serum creatinine of ≤ 0.5 mg/dL from baseline were observed in most patients. Increased creatinine usually occurs transiently during treatment or resolves after treatment is discontinued.
In the DECLARE clinical trial, which included elderly patients and patients with renal impairment (eGFR less than 60mL/min/1.73m2?), eGFR decreased over time in both the dapagliflozin group and the placebo group. After 1 year, the average eGFR was slightly lower in the dapagliflozin group, and after 4 years, the average eGFR in the dapagliflozin group was slightly higher than the placebo group.
In the DAPA-HF clinical trial, eGFR decreased over time in both the dapagliflozin group and the placebo group. The initial decrease in mean eGFR was -4.3 mL/min/1.73 m2 in the dapagliflozin group and -1.1 mL/min/1.73 m2 in the placebo group. At 20 months, the change in eGFR from baseline was similar between treatment groups (dapagliflozin group -5.3 mL/min/1.73 m2, placebo group -4.5 mL/min/1.73 m2).
In the DAPA-CKD clinical trial, eGFR decreased over time in both the dapagliflozin group and the placebo group. The initial (day 14) decrease in average eGFR was -4.0 mL/min/1.73 m2 in the dapagliflozin group and -0.8 mL/min/1.73 m2 in the placebo group. At 28 months, the change in eGFR compared to baseline was -7.4mL/min/1.73m2 in the dapagliflozin group and -8.6mL/min/1.73m2 in the placebo group.
⑦ Perineal gangrene (Fournier’s gangrene)
During post-marketing surveillance, cases of Fournier's gangrene have been reported in patients receiving SGLT2 inhibitors, including dapagliflozin (see 5. General precautions, 11) Perineal gangrene (Fournier's gangrene).
In the DECLARE clinical trial involving 17,160 patients with type 2 diabetes and a median exposure period of 48 months, a total of 6 cases of Fournier's gangrene were reported, including 1 case in the dapagliflozin group and 5 cases in the placebo group.
(4) Post-marketing surveillance
The following are additional adverse drug reactions confirmed after the marketing of dapagliflozin. This adverse drug reaction was reported voluntarily from an uncharacteristic large population, so it is not possible to reliably predict its incidence.
- Ketoacidosis (including diabetic ketoacidosis)
- Urosepsis and pyelonephritis
- Acute kidney injury and renal dysfunction
- Rash: Rash includes the following representative terms in order of frequency in clinical studies: rash, generalized rash, pruritic rash, macular rash, maculopapular rash, pustular rash, bullous rash, and erythematous rash. In active-controlled and placebo-controlled clinical studies (5,936 people in the dapagliflozin group, 3,403 people in all control groups), the frequency of rash was similar in the dapagliflozin group (1.4%) and all control groups (1.4%) and was ‘common.’
(5) Domestic post-marketing survey results
As a result of a post-marketing survey conducted on 3,027 people over 6 years for re-examination in Korea, the occurrence rate of adverse events was reported to be 26.59% (805/3,027 people, total 1,122 cases) regardless of causal relationship. Among these, serious adverse events unrelated to a causal relationship and serious adverse drug reactions for which a causal relationship cannot be ruled out are listed in the table below according to the frequency of occurrence.
*Table: Refer to attached document
In addition, unexpected adverse events unrelated to causal relationships and unexpected adverse drug reactions for which causal relationships cannot be ruled out are listed in the following table according to the frequency of occurrence.
*Table: Refer to attached document
2) Sitagliptin
(1) Clinical trials
① Because clinical trials are conducted under wide and diverse conditions, the incidence of adverse reactions observed in clinical trials cannot be directly compared to the rates in clinical trials of other drugs, and cannot reflect the rates observed under actual use environments.
In clinical trials of sitagliptin, when sitagliptin was administered as monotherapy or combination therapy (metformin or pioglitazone or rosiglitazone and metformin), the incidence of adverse reactions and hypoglycemia was generally similar to that reported for placebo. Cases where treatment was discontinued due to adverse reactions were similar to those in the placebo group.
During glimepiride or glimepiride and metformin combination therapy, the frequency of adverse reactions in the sitagliptin group was higher than the placebo group (Table 4). This is partly due to the high incidence of hypoglycemia in the sitagliptin administration group. Discontinuation of treatment due to adverse reactions was similar to that in the placebo group.
Two placebo-controlled monotherapy studies conducted for 18 and 24 weeks included groups receiving sitagliptin 100 mg and 200 mg daily and placebo. Five additional placebo-controlled combination therapy studies administered 100 mg of sitagliptin or placebo daily in combination with stable doses of metformin, pioglitazone, rosiglitazone, and metformin, glimepiride (±metformin), or insulin (±metformin), respectively.
In these clinical trials, except for hypoglycemia and regardless of causality assessment, adverse reactions reported at a frequency of 5% or more among patients taking sitagliptin 100 mg daily for 18 weeks and more frequently than placebo are listed in Table 2. The frequency of occurrence of hypoglycemia is shown in Table 4.
Table 2. Placebo-controlled clinical trials with sitagliptin monotherapy or in combination (pioglitazone, or rosiglitazone and metformin, or glimepiride (±metformin)): Adverse events, excluding hypoglycemia, reported at a frequency greater than 5% and more frequently than placebo, regardless of causality assessment†
*Table 2: Refer to attached document
† ITT (Intent-to-treat) subject group
In patients who received sitagliptin and metformin in combination for 24 weeks, there were no adverse reactions reported at a frequency of more than 5% and more frequently than placebo, regardless of causality assessment.
In patients who received sitagliptin in combination with a stable dose of insulin (±metformin) for 24 weeks, there were no adverse reactions except hypoglycemia, which was reported at a frequency of more than 5% and more frequently than placebo, regardless of causality assessment (see Table 4 for hypoglycemia). In patients receiving additional sitagliptin during another 24-week insulin intensification period (±metformin), the adverse reaction reported at a frequency greater than 5% and more frequently than placebo, regardless of causality assessment, was diarrhea (sitagliptin 5.2%; placebo 3.3%).
In patients receiving sitagliptin in combination with rosiglitazone and metformin for 54 weeks, adverse reactions reported at a frequency of 5% or more and more frequently than placebo, regardless of causality assessment, were: upper respiratory tract infection (sitagliptin 15.5%, placebo 6.2%), nasopharyngitis (11.0%, 9.3%), peripheral edema (8.3%, 5.2%), and headache. (5.5%, 4.1%).
As a result of a comprehensive analysis of two monotherapy clinical trials, a clinical trial with additional combination therapy with metformin, and a clinical trial with additional combination therapy with pioglitazone, the occurrence of specific gastrointestinal adverse reactions in patients treated with sitagliptin was as follows: abdominal pain (sitagliptin 100 mg 2.3%, placebo 2.1%), nausea (sitagliptin 100 mg 1.4%, placebo 0.6%), Diarrhea (sitagliptin 100mg 3.0%, placebo 2.3%)
In a placebo-controlled factorial design clinical trial conducted for 24 weeks, adverse reactions reported at a frequency of 5% or more or more frequently than placebo, regardless of causality assessment, upon initial co-administration of sitagliptin and metformin are shown in Table 3.
Table 3. Initial combination therapy with sitagliptin and metformin: Adverse reactions reported at a frequency of 5% or more and more frequently than sitagliptin alone, metformin alone, or placebo, regardless of causality assessment†
*Table 3: Refer to attached document
† ITT (Intent to treat) subject group
‡ Integrated data of patients receiving low and high doses of metformin
No clinically significant changes in vital signs or ECG (including QTc interval) were observed with sitagliptin administration.
② Pancreatitis
When the results of 19 double-blind clinical trials of 10,246 patients randomly assigned to sitagliptin 100 mg/day (N=5429) or the corresponding control group (active comparator or placebo) (N=4817) were pooled and analyzed, the incidence of acute pancreatitis in each group was 0.1 per 100 patient-years (in the sitagliptin group) reported in 4 patients out of 4708 patient-years and in the control group in 4 patients out of 3942 patient-years). In the TECOS cardiovascular safety trial, the incidence of acute pancreatitis was reported to be 0.11 (23/7,332, 25 cases) per 100 patient-years in the sitagliptin group and 0.06 (12/7,339, 17 cases) per 100 patient-years in the placebo group. (See 1. Warning, 1) Sitagliptin, (2) Pancreatitis section, and TECOS Cardiovascular Safety Clinical Trial section)
③ TECOS cardiovascular safety clinical trial (TECOS: Trial Evaluating Cardiovascular Outcomes with Sitagliptin)
The intent-to-treat (ITT) arm of the sitagliptin cardiovascular safety clinical trial included 7,332 patients who received sitagliptin 100 mg daily (or 50 mg daily if eGFR ≥ 30 and < 50 mL/min/1.73 m2 at baseline) and 7,339 patients who received placebo. In this trial, sitagliptin or placebo was administered in addition to usual treatment in each country related to HbA1c and cardiovascular (CV) risk factors. Sitagliptin administration did not increase the risk of hospitalization due to major cardiovascular disease or heart failure. The reported incidence of serious adverse reactions was similar at 12.7% in the sitagliptin group and 12.4% in the placebo group.
Severe hypoglycemia was reported in 2.2% of the sitagliptin group (160 patients; 0.78 per 100 patient-years) and 1.9% of the placebo group (143 patients; 0.70 per 100 patient-years). Among patients receiving insulin and/or a sulfonylurea, the incidence was 2.7% with sitagliptin (138/5,021 patients) and 2.5% with placebo (125/4,931 patients). Among patients not receiving insulin or a sulfonylurea, the incidence was 1.0% with sitagliptin (22/2,311 patients) and 0.7% with placebo (18/2,408 patients). Confirmed acute pancreatitis occurred in 0.3% of the sitagliptin group and 0.2% of the placebo group.
④ Low blood sugar
In all studies (9), hypoglycemic adverse events were based on reports of symptomatic hypoglycemia. Although blood sugar measurement was not necessarily involved, most reports of hypoglycemia (74%) were below 70 mg/dL when measured. When sitagliptin was administered in combination with a sulfonylurea or insulin, the proportion of patients with one or more hypoglycemic adverse events was higher than in the placebo group (see Table 4).
Table 4. Placebo-controlled trials of sitagliptin in combination with glimepiride (±metformin) or insulin (±metformin): reported incidence of hypoglycemia, regardless of causality assessment†
*Table 4: Refer to attached document
† Hypoglycemic adverse events were based on reports of symptomatic hypoglycemia and were not necessarily accompanied by blood glucose measurements; ITT (Intent to treat) group
‡ Based on total number of incidents (a person may report multiple incidents)
§ Severe hypoglycemia was defined as requiring medical attention, reaching a reduced level of consciousness, losing consciousness, or having a seizure.
As a result of a comprehensive analysis of two monotherapy clinical trials, a clinical trial with additional combination therapy with metformin, and a clinical trial with additional combination therapy with pioglitazone, the incidence of hypoglycemia as an adverse reaction in patients administered sitagliptin 100 mg was similar to that of placebo (1.2% for sitagliptin 100 mg, 0.9% for placebo).
In a clinical trial of the combination therapy of sitagliptin, rosiglitazone, and metformin, the incidence of hypoglycemia up to 18 weeks was 2.2% in the sitagliptin group and 0.0% in the placebo group. The incidence up to 54 weeks was 3.9% and 1.0%, respectively.
In a placebo-controlled factorial trial conducted for 24 weeks, the incidence of hypoglycemia during initial co-administration of sitagliptin and metformin was 0.6% in the placebo group, 0.6% in the sitagliptin-only group, 0.8% in the metformin-only group, and 1.6% in the sitagliptin-metformin combination group.
⑤ Laboratory tests
The incidence of laboratory adverse reactions in the group administered 100 mg of sitagliptin was 8.2%, and in the group administered placebo it was 9.8%. In clinical trials, a slight increase in white blood cell count (approximately 200 cells/μL difference compared to placebo administration; average baseline value of approximately 6600 cells/μL) was observed due to an increase in neutrophils. This difference has been shown in many, but not all, studies, and changes in laboratory values are not believed to be clinically relevant.
In a 12-week study, 91 patients with chronic renal impairment and 37 patients with moderate renal impairment were randomly assigned to sitagliptin 50 mg, and 14 patients with the same degree of renal impairment were randomized to placebo. The mean (standard error) increase in serum creatinine was 0.12 mg/dL (0.04) in the sitagliptin group and 0.07 mg/dL (0.07) in the placebo group. The clinical significance of increased serum creatinine compared to placebo is unknown.
⑥ Domestic clinical trial results
The safety and efficacy of sitagliptin were evaluated in a bridging clinical trial conducted in 530 Asians in a multinational, double-blind, randomized, placebo-controlled, parallel group study, of which 95 were Korean. The safety profile of sitagliptin in Koreans was overall similar to that of placebo and did not show significant differences from the results reported in previous clinical trials.
(2) Post-marketing adverse reactions
The following are additional adverse reactions confirmed after the marketing of sitagliptin. Because these adverse reactions are voluntarily reported from an unspecified population, it is generally not possible to reliably predict their frequency or establish a causal relationship with drug exposure. Hypersensitivity reactions, including anaphylaxis, angioedema, rash, urticaria, cutaneous angiitis and exfoliative skin diseases including Stevens-Johnson syndrome (see section 1. Warnings), elevated liver enzymes; Acute pancreatitis, including fatal/non-fatal hemorrhagic or necrotizing pancreatitis (see 1. Warning, 1) Sitagliptin, (2) Pancreatitis); Deterioration of renal function, including acute renal failure (sometimes requiring dialysis); upper respiratory tract infection; nasopharyngitis; constipation; puke; headache; Severe and disabling arthralgia (see section 5. General precautions, section 12) Severe and disabling arthralgia); Bullous pemphigoid (see section 5. General precautions, 13) Bullous pemphigoid); myalgia; Pain in limbs; back pain; interstitial lung disease; pruritus; It is thrombocytopenia. During post-marketing use, rhabdomyolysis was reported when taken with statin drugs. (Domestic clue information analysis and evaluation results)
(3) Domestic post-marketing survey results
① As a result of a use result survey conducted on 3,453 people over 6 years for re-examination in Korea, the incidence of adverse events was reported to be 4.87% (168/3,453 people) [232 cases] regardless of causal relationship, and among these, the incidence of adverse drug reactions for which a causal relationship with sitagliptin could not be ruled out was 1.56% (54/3,453 people). [64 cases] ‘hypoglycemia’ at 0.26% (9 people/3,453 people) [9 cases], ‘indigestion’ and ‘dizziness’ at 0.12% each (4/3,453 people) [4 cases], ‘increased ALT’, ‘AST increase’, ‘diarrhea’, ‘nausea’, and ‘headache’ at 0.09% each (3/3,453 people) [3 cases], etc. It has been reported.
Serious adverse events were 0.12% (4/3,453 people) [5 cases] regardless of causal relationship, with ‘pneumonia’, ‘diabetic complications’, ‘metabolic acidosis’, ‘fall’, and ‘cardiac arrest’ occurring at 0.03% (1/3,453 people) [1 case] each. Among these, the serious adverse drug reaction was ‘diabetic complications’ at 0.03%. (1/3,453 people)[1 case] reported.
Unexpected adverse events were reported at 3.04% (105/3,453 people) [137 cases] regardless of causal relationship, ‘indigestion’ at 0.32% (11/3,453 people) [12 cases], ‘dizziness’ at 0.23% (8/3,453 people) [8 cases], ‘increased blood triglyceride’, and ‘gastritis’. 0.17% (6/3,453 people) [6 cases] were reported, and among these, unexpected adverse drug reactions for which a causal relationship with sitagliptin cannot be ruled out were 0.93% (32/3,453 people) [35 cases], ‘indigestion’ and ‘dizziness’ at 0.12% (4/3,453 people) [4 cases] respectively, ‘increased blood triglycerides’, ‘Increased low-density lipoprotein’ and ‘hyperglycemia’ were reported in the order of 0.06% (2/3,453 people) [2 cases] each.
② As a result of integrated evaluation of the domestic re-examination adverse event and spontaneous side effect reporting data for sitagliptin with the adverse event reporting data reported for all domestically approved drugs at the end of re-examination, the following are newly identified adverse events that were statistically significantly more reported for sitagliptin than those reported for all other drugs. However, this result does not mean that a causal relationship has been proven between the ingredient and the following adverse events.
· Gastrointestinal disorders: indigestion, gastritis
· Metabolic and nutritional diseases: weight loss
· Common cardiovascular diseases: high blood pressure
· Metabolic and nutritional diseases: hypernatremia
· Mental illness: erectile dysfunction
3) Metformin
In post-marketing surveillance and clinical trial results, the side effects reported in patients receiving metformin hydrochloride extended-release tablets were similar in content and severity to the side effects reported in patients receiving metformin hydrochloride immediate-release tablets.
The following side effects may occur when receiving metformin:
Frequency is defined as follows: Very common: >1/10 Common: >1/100, <1/10 Uncommon: >1/1,000, <1/100 Rare: >1/10,000, <1/1,000 Very rare: <1/10,000
(1) Metabolic and nutritional disorders
Common: vitamin B12 deficiency
Very rare: Lactic acidosis (see section 5. General precautions)
(2) nervous system disorders
Common: taste impairment
(3) Gastrointestinal disorders
Very common: Gastrointestinal disorders such as nausea, vomiting, diarrhea, abdominal pain and anorexia (see Section 5. General precautions)
(4) Skin and subcutaneous tissue disorders
Very rarely: erythema, itching, urticaria, rash, etc. may occur. In such cases, discontinue administration.
5. General precautions
1) Lactic acidosis
Lactic acidosis is a rare but serious metabolic complication that occurs due to metformin accumulation during metformin treatment. In 50% of cases, it is fatal. Lactic acidosis occurs frequently in acute renal dysfunction, cardiopulmonary disease, and sepsis. Lactic acidosis may occur when there is significant tissue hypoperfusion and hypoxia and in conjunction with pathophysiological conditions, including diabetes. Lactic acidosis is characterized by increased blood lactic acid concentration (over 5 mmol/L), decreased blood pH, electrolyte imbalance with increased difference between anions, and increased lactic acid/pyruvate ratio. When metformin is believed to be the cause of lactic acidosis, metformin blood levels generally exceed 5 μg/mL.
There are very few reports of the development of lactic acidosis in patients receiving metformin (approximately 0.03 cases per 1,000 patients per year and approximately 0.015 fatal cases per 1,000 patients per year). The reported cases primarily occurred in diabetic patients with significantly reduced renal function, including intrinsic renal disease and renal hypoperfusion, in conditions such as multiple medical and surgical problems and combined administration of many drugs. The risk of lactic acidosis increases with the degree of renal function decline and the patient's age.
In addition, metformin should be discontinued immediately if symptoms related to hypoxia, dehydration, or sepsis appear. If liver function is impaired, the ability to excrete lactic acid may be significantly reduced, so this drug is generally not administered to patients with clinical or laboratory findings of liver disease. Since alcohol has the potential to affect metformin's lactic acid metabolism, acute or chronic excessive intake of alcohol should be avoided while taking this drug.
The onset of lactic acidosis is sometimes difficult to distinguish and is accompanied by nonspecific symptoms such as malaise, myalgia, dyspnea, asthenia, and abdominal pain. If acidosis becomes more severe, a drop in body temperature, hypotension, and resistant bradyarrhythmia may occur. Patients and doctors should be aware of the importance of these symptoms, and patients should notify their doctors immediately if these symptoms occur. Serum electrolytes, ketones, blood sugar, blood pH (<7.35), lactic acid concentration, and blood metformin concentration may also be useful in confirming lactic acidosis. Additionally, if there is a high suspicion of lactic acidosis, necessary measures are taken without expecting a lactic acid measurement result. In particular, be careful because lactic acidosis is likely to occur when the initial dose is increased. Gastrointestinal symptoms often occur early in treatment once the patient has stabilized on a specific dose of metformin, but later gastrointestinal symptoms may be due to lactic acidosis or another serious illness.
Fasting venous plasma lactate concentrations above the upper limit of normal but below 5 mmol/L in patients receiving metformin do not indicate impending lactic acidosis and may be due to other mechanisms, such as poorly controlled diabetes or obesity, excessive physical activity, or technical problems in specimen handling. Lactic acidosis should be suspected in diabetic patients presenting with metabolic acidosis without evidence of ketoacidosis (ketonuria and ketonemia).
Lactic acidosis is a medical emergency requiring hospitalization. If lactic acidosis occurs in a patient taking this drug, the drug should be discontinued immediately and general supportive treatment should be administered immediately. Because metformin is dialyzable (clearance reaching 170 mL/min in good hemodynamic conditions), immediate hemodialysis is recommended to normalize acidosis and remove accumulated drug. This treatment sometimes results in immediate symptom improvement and recovery.
2) Monitoring of renal function
Metformin and sitagliptin are mostly excreted by the kidneys, and the risk of metformin accumulation and lactic acidosis increases depending on the degree of renal dysfunction. The effectiveness of dapagliflozin on blood sugar varies depending on renal function. Patients with serum creatinine levels above the upper limit of normal for their age should not take this drug. Before starting treatment with this drug, and at least annually, renal function should be evaluated and confirmed normal. Patients with creatinine clearance lower than normal and the elderly should have a renal function test performed at least 2 to 4 times a year. If creatinine clearance <45ml/min or glomerular filtration rate <45ml/min/1.73m2), discontinue treatment with this drug. Special caution is needed in situations that may lead to rapid renal function impairment, such as those experiencing dehydration (severe or persistent vomiting or diarrhea) or starting medications that affect renal function (such as antihypertensive drugs or diuretics and nonsteroidal anti-inflammatory drugs (NSAIDs)). In these acute situations, administration of this drug should be discontinued immediately and temporarily.
3) Use in patients at risk of volume loss and/or hypotension
Due to the mechanism of action of dapagliflozin, an increase in urination leading to a slight decrease in blood pressure was observed in clinical studies. This may be more noticeable in patients with very high blood sugar levels.
Caution should be exercised in patients who may be at risk for drug-induced reductions in blood pressure, such as patients receiving antihypertensive treatment and a history of hypotension or elderly patients.
If there are comorbidities that may cause volume loss (e.g., gastrointestinal disease), close monitoring of fluid volume status (e.g., physical examination, blood pressure measurement, and laboratory tests including hematocrit and electrolyte testing) is recommended. For patients exhibiting volume loss, temporary discontinuation of dapagliflozin is recommended until volume loss is restored.
4) Action on the liver
Monitoring of liver enzymes is recommended in all patients prior to initiating therapy with this drug, and thereafter at regular intervals based on the clinical judgment of the physician.
(1) Dapagliflozin
Clinical trial experience in patients with hepatic impairment is limited. Dapagliflozin exposure is increased in patients with severe hepatic impairment.
(2) Metformin
Metformin is contraindicated in patients with hepatic impairment because its use has been associated with some cases of lactic acidosis.
5) Ketoacidosis
Reports of serious, life-threatening ketoacidosis requiring prompt hospitalization have been identified in patients with type 1 and type 2 diabetes treated with SGLT2 inhibitors, including dapagliflozin. Fatal cases of ketoacidosis have been reported in patients treated with dapagliflozin.
Dapagliflozin-associated ketoacidosis may occur even when blood glucose is below 250 mg/dL. Patients treated with dapagliflozin who show signs and symptoms consistent with severe metabolic acidosis should therefore be evaluated for ketoacidosis regardless of their blood glucose level. If ketoacidosis is suspected, discontinue dapagliflozin, assess the patient’s condition and initiate treatment promptly.
Treatment of ketoacidosis may require insulin, fluid, and carbohydrate replacement.
In many post-marketing reports, particularly in patients with type 1 diabetes, the presence or absence of ketoacidosis was not immediately identified and the introduction of treatment was delayed because the observed blood glucose levels were lower than those typically expected for diabetic ketoacidosis (most often less than 250 mg/dL).
Diabetes and ketoacidosis may persist longer than is generally expected, and urinary glucose secretion may persist for up to 3 days after discontinuation of treatment. However, there have been post-marketing reports that diabetes and ketoacidosis persisted for more than 6 days and up to 2 weeks after discontinuation of SGLT2 inhibitor treatment. Symptoms and signs of ketoacidosis are consistent with dehydration and severe metabolic acidosis and include nausea, vomiting, decreased appetite, abdominal pain, malaise, and difficulty breathing. Some reports have identified factors predisposing to ketoacidosis to include reduced insulin dose, acute febrile illness, restricted calorie intake due to illness or surgery, ketogenic diet, pancreatic disorders causing insulin deficiency (e.g., type 1 and 2 diabetes, pancreatitis, or history of pancreatic surgery), and alcohol abuse.
Before starting dapagliflozin treatment, factors that may predispose to ketoacidosis, including decreased insulin secretion, calorie restriction, and alcohol abuse, should be considered. Monitor patients treated with dapagliflozin for the development of ketoacidosis, and consider temporarily discontinuing dapagliflozin administration if clinical situations predisposing to ketoacidosis (e.g., prolonged fasting due to acute illness or surgery) occur.
Inform patients about the risk of diabetic ketoacidosis, its risk factors, signs and symptoms, and the fact that it may occur even when blood glucose is below 250 mg/dL. It is recommended that patients be able to monitor blood ketones and receive education on when monitoring is needed. Patients should seek prompt treatment if ketoacidosis is suspected.
6) Urosepsis and pyelonephritis
Serious urinary tract infections, including urosepsis and pyelonephritis, have been reported post-marketing in patients using dapagliflozin and other SGLT2 inhibitors. SGLT2 inhibitor therapy increases the risk of urinary tract infections. If necessary, evaluate the patient's signs and symptoms of urinary tract infection and promptly treat them.
7) Reproductive infections (including fungi)
Dapagliflozin increases the risk of genital infections (including fungal). Patients with a history of genital infections (including fungal) are more likely to develop genital infections (including fungal). Observe and treat appropriately.
8) Urine laboratory evaluation
Patients receiving dapagliflozin will test positive for urinary glucose due to its mechanism of action.
9) SGLT2 inhibitors such as dapagliflozin may theoretically worsen the condition of patients with underlying bladder diseases that may affect urinary function by increasing urine volume. Therefore, caution is required when prescribing SGLT2 inhibitors such as dapagliflozin to these patients.
10) Lower limb amputation
In long-term clinical studies of other SGLT2 inhibitors in patients with type 2 diabetes, an increase in lower extremity amputations (mainly toes) was observed. It has not been confirmed whether this case applies to the entire series. It is important to discuss routine preventive foot care with patients with diabetes.
11) Perineal gangrene (Fournier’s gangrene)
In post-marketing surveillance of diabetic patients taking SGLT2 inhibitors, rare cases of serious, life-threatening perineal gangrene requiring prompt surgical intervention were reported [4. Adverse reactions, 1) Dapagliflozin, (3) Description of specific adverse reactions, ⑦ Perineal gangrene (Fournier gangrene)]. Perineal gangrene has been reported in both men and women, resulting in hospitalization, multiple surgeries, and death.
If a patient receiving dapagliflozin develops pain, soreness, erythema, or swelling around the genitals or perineum along with fever and discomfort, perineal gangrene should be checked. If perineal gangrene is suspected, broad-spectrum antibiotic treatment should be started immediately and surgical resection should be performed if necessary. Administration of dapagliflozin should be discontinued, blood sugar levels should be closely monitored, and appropriate alternative treatment should be implemented to control blood sugar.
12) Severe and disabling joint pain
Severe and disabling arthralgia have been reported in post-marketing studies in patients taking DPP-4 inhibitors. The onset of symptoms after drug administration varied from 1 day to several years later. Symptoms were alleviated when drug administration was stopped. In some patients, recurrence of symptoms occurred when taking the same drug or a different DPP-4 inhibitor. Consider the DPP-4 inhibitor as the cause of severe arthralgia and, if appropriate, discontinue administration.
13) Bullous pemphigoid
In post-marketing surveillance in patients taking DPP-4 inhibitors, cases of bullous pemphigus requiring hospitalization have been reported. Patients generally recovered with discontinuation of DPP-4 inhibitors and treatment with topical or systemic immunosuppressants. Patients should be informed to immediately report to their doctor if blisters or sores occur while taking sitagliptin. If bullous pemphigus is suspected, sitagliptin should be discontinued and the patient should be referred to a dermatologist for diagnosis and appropriate treatment.
14) Hypoxic state: Cardiovascular collapse (shock) of any cause, acute congestive heart failure, acute myocardial infarction and other conditions characterized by hypoxia are associated with lactic acidosis and may cause prerenal azotemia. If this occurs in a patient receiving treatment with this drug, administration of this drug should be discontinued immediately.
15) Cardiac function: Patients with heart failure have a higher risk of hypoxia and decreased renal function. For patients with stable chronic heart failure, metformin can be administered with regular monitoring of heart and kidney function.
16) Alcohol intake: Alcohol is known to increase the effect of metformin on lactic acid metabolism. Therefore, acute or chronic excessive intake of alcohol should be avoided while taking this medicine.
17) Vitamin B12 levels: It is recommended to monitor serum vitamin B12 levels annually. The risk of low vitamin B12 levels increases in patients with higher metformin doses, longer treatment duration, and/or with risk factors known to cause vitamin B12 deficiency.
18) Hypoglycemia: Hypoglycemia does not occur in patients who take metformin alone under normal use circumstances, but occurs when caloric intake is insufficient, when vigorous exercise is not supplemented by caloric intake, or when other hypoglycemic agents (sulfonylurea, insulin, meglitinide, etc.) or alcohol are administered concurrently. Hypoglycemia is especially likely to occur in the elderly, weak or malnourished patients, patients with adrenal or pituitary insufficiency, or alcoholics. Hypoglycemia may be difficult to identify in older adults and people taking β-adrenergic blocking drugs. When symptoms of hypoglycemia are recognized due to administration of metformin, sugar (sucrose) is generally administered, and when symptoms of hypoglycemia are recognized due to concurrent use with an α-glucosidase inhibitor (acarbose, voglibose), glucose is administered.
19) Gastrointestinal disorders
When administering metformin, gastrointestinal disorders such as nausea, vomiting, diarrhea, abdominal pain, and anorexia occur most frequently in the early stages of treatment and disappear spontaneously in most cases. Gradually increasing the dose may help increase gastrointestinal tolerability. Since gastrointestinal symptoms occur in a dose-related manner during the initial stage of treatment, they can be reduced by gradually increasing the dose or administering metformin with meals. Severe diarrhea and/or vomiting may cause dehydration and prerenal azotemia and should be temporarily discontinued under these conditions. In patients stabilized on metformin, non-specific gastrointestinal symptoms may not be due to treatment but may be due to concurrent disease or lactic acidosis.
20) Changes in controlled diabetic patients: If abnormal laboratory findings or clinical disease (especially vague and poorly defined disease) occurs in a patient whose type 2 diabetes was previously well controlled with this drug, the patient should be immediately evaluated for the development of ketoacidosis or lactic acidosis. Serum electrolytes, ketones, and blood sugar are tested, and, if necessary, blood pH, lactate, pyruvate, and metformin levels. If any form of acidosis appears, immediately discontinue metformin administration and take other appropriate and correct measures.
21) Co-administration with drugs that may affect renal function or metformin metabolism or excretion: Co-administration with drugs that may affect renal function, cause significant hemodynamic changes, or inhibit the metabolism or excretion of metformin, such as cationic drugs excreted through renal tubular discharge, should be used with caution (see Section 6. Interactions).
22) Patients with specific occupations: In rare cases, severe lactic acidosis and severe delayed hypoglycemia may occur, so caution should be exercised when administering to patients engaged in work at heights or driving a car. In addition, provide sufficient and thorough warning to patients and their families regarding lactic acidosis and hypoglycemia.
23) This medicine should be swallowed whole rather than crushed or chewed. Patients should be informed in advance that this is normal as the tablet shell may pass through the stool.
6. Interaction
1) Dapagliflozin
(1) Pharmacodynamic interaction
① Diuretics: Dapagliflozin may increase the diuretic effect of thiazides and loop diuretics and may increase the risk of dehydration and hypotension.
② Insulin and insulin secretion stimulants: Insulin secretion stimulants such as insulin and sulfonylureas can cause hypoglycemia. Therefore, to reduce the risk of hypoglycemia when administered in combination with dapagliflozin, the dose of insulin or insulin secretagogue may need to be reduced.
(2) Pharmacokinetic interactions
① The metabolism of dapagliflozin is mainly accomplished through glucuronide conjugation mediated by UDP-glucuronidase 1A9 (UGT1A9).
② In laboratory (in-vitro) studies, dapagliflozin did not inhibit cytochrome P450 (CYP) 1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A4, or induce CYP1A2, CYP2B6, or CYP3A4. Therefore, dapagliflozin is not expected to alter the metabolic excretion of drugs metabolized by these enzymes when coadministered with these drugs.
(3) Effects of other medicines on dapagliflozin
① As a result of an interaction study conducted on healthy subjects mainly using a single-dose design, the pharmacokinetics of dapagliflozin were not changed by metformin, pioglitazone, sitagliptin, glimepiride, voglibose, hydrochlorothiazide, bumetanide, valsartan, or simvastatin.
② After co-administering dapagliflozin with rifampicin (an inducer of various active transporters and drug-metabolizing enzymes), a 22% decrease in dapagliflozin systemic exposure (AUC) was observed, but there was no clinically significant effect on 24-hour urinary glucose excretion. Dosage adjustments are not recommended. Clinically relevant effects are not expected with other inducers (e.g., carbamazepine, phenytoin, phenobarbital).
③ After co-administering dapagliflozin with mefenamic acid (an inhibitor of UGT1A9), systemic exposure to dapagliflozin increased by 55%, but there was no clinically significant effect on 24-hour urinary glucose excretion. Dosage adjustments are not recommended.
(4) Effect of dapagliflozin on other medicines
Dapagliflozin may increase renal excretion of lithium and decrease blood lithium concentrations. Serum lithium concentrations should be monitored more frequently upon initiation of dapagliflozin and after dose changes. Refer the patient to the doctor who prescribed lithium to monitor serum lithium levels.
In interaction studies conducted in healthy subjects, primarily using a single-dose design, dapagliflozin had an anticoagulant effect on the pharmacokinetics of metformin, pioglitazone, sitagliptin, glimepiride, hydrochlorothiazide, bumetanide, valsartan, digoxin (a P-gp substrate), or warfarin (S-warfarin, a CYP2C9 substrate), or the anticoagulant activity of warfarin as assessed by INR. didn't change A single co-administration of dapagliflozin 20 mg and simvastatin (CYP3A4 substrate) resulted in a 19% increase in simvastatin AUC and a 31% increase in simvastatin acid AUC. Elevated simvastatin and simvastatin acid exposure are not considered clinically relevant.
(5) Other interactions
The effects of smoking, diet, herbal medicines and alcohol on the pharmacokinetics of dapagliflozin have not been studied.
(6) Pediatrics
Interaction studies were conducted only in adults.
(7) Interference with 1,5-anhydroglucitol test
The 1,5-anhydroglucitol test is not recommended as a blood sugar control monitoring test in patients taking SGLT2 inhibitors because the reliability of the measurement results is low. Different methods are used to monitor blood sugar control.
2) Sitagliptin
In drug interaction studies, sitagliptin did not have a clinically significant effect on the pharmacokinetics of the following drugs: metformin, rosiglitazone, glibenclamide, simvastatin, warfarin, and oral contraceptives. Based on this test, it is not expected to act on substrates of CYP3A4, CYP2C8, CYP2C9 and organic cation transporters.
Co-administration of metformin and sitagliptin taken twice daily in patients with type 2 diabetes does not significantly change the pharmacokinetics of sitagliptin.
Cyclosporine: When administered as a single dose in combination with 600 mg of cyclosporine, a strong p-glycoprotein inhibitor, the AUC (29%) and Cmax (68%) of sitagliptin were increased, but the change in the pharmacokinetics of sitagliptin is not expected to be clinically significant. No significant interaction is expected when coadministered with cyclosporine or other p-glycoprotein inhibitors.
Digoxin: When coadministered with 100 mg of sitagliptin for 10 days, the plasma AUC (11%) and Cmax (18%) of digoxin increased slightly. Appropriate monitoring should be conducted when administering digoxin, and dose adjustment of sitagliptin and digoxin is not necessary.
3) Metformin
(1) Since the blood sugar-lowering effect may be enhanced or decreased by combined use with the following drugs, when used together, administer while carefully observing the blood sugar level and the condition of other patients.
- Drugs that increase blood sugar lowering action
Insulin preparations, sulfonylamide and sulfonylurea drugs, meglitinides (repaglinide, etc.), β-blockers (propranolol, etc.), MAO inhibitors, alpha-glycosidase inhibitors (alkalophos), anabolic steroids, guanethidine, salicylates (aspirin, etc.),
- Drugs that reduce blood sugar lowering action
Epinephrine, sympathomimetics, corticosteroids, thyroid hormones, follicular hormones, estrogens, oral contraceptives, thiazide and other diuretics, pyrazinamide, isoniazid, nicotinic acid, phenothiazines, phenytoin, calcium channel antagonists.
(2) Alcohol: The risk of lactic acidosis increases during the acute alcohol intoxication period, especially in the following circumstances.
- Hungry or malnutrition
- Liver dysfunction
You should avoid drinking alcohol and taking drugs that contain alcohol.
(3) Iodine-labeled contrast media: Renal failure may occur in association with intravenous administration of iodine-labeled contrast media, which may cause metformin accumulation and may expose patients to the risk of lactic acidosis. Metformin should be discontinued before or at the time of testing with iodine-labeled contrast media, and treatment should be resumed only after at least 48 hours and after reassessment of renal function and determination that there is no risk of further damage. (Refer to 2. Do not administer to the following patients.)
(4) Glyburide: In a single-dose study on patients with type 2 diabetes, co-administration of metformin and glyburide did not cause changes in the pharmacokinetics or pharmacodynamic properties of metformin. A decrease in the AUC and Cmax of glyburide was observed, but the deviation was large. The lack of correlation between blood concentrations and pharmacokinetic effects of metformin after a single dose in this study indicates that the clinical significance of this interaction is unclear.
(5) Furosemide: A study on the drug interaction of metformin and furosemide administered as a single dose in healthy people showed that the pharmacokinetic values of each substance were affected by co-administration. Furosemide increases the plasma concentration of metformin without significant changes in the renal clearance of metformin, and increases blood Cmax by 22% and blood AUC by 15%. When co-administered with metformin, the Cmax and AUC of furosemide are reduced by 31% and 12%, respectively, compared to single administration, and the terminal half-life of furosemide is reduced by 32% without changing the renal clearance of furosemide. There is no available information regarding the interaction when metformin and furosemide are co-administered chronically.
(6) Nifedipine: A study on the drug interaction between metformin and nifedipine in a single dose in normal healthy volunteers showed that co-administration with nifedipine increases the Cmax and AUC of metformin in plasma by 20% and 9%, respectively, and increases urinary excretion. Tmax and half-life are not affected. Nifedipine promotes the absorption of metformin. Metformin does not significantly affect nifedipine.
(7) Drugs that may affect metformin, such as cationic drugs that may affect renal function, cause significant hemodynamic changes, or are excreted through renal tubular secretion: Metformin is a substrate of the organic cation transporter (OCT) OCT1 and OCT2.
- When used in combination with OCT1 inhibitors (verapamil, etc.), the efficacy of metformin may be reduced.
- When used in combination with OCT1 inducers (rifampicin, etc.), the gastrointestinal absorption and efficacy of metformin may increase.
- When used in combination with OCT2 inhibitors (cimetidine, dolutegravir, ranolazine, trimethoprim, vandetanib, isavuconazole, etc.), the renal excretion of metformin may be reduced and the blood concentration of metformin may increase.
- When used in combination with OCT2 and OCT1 simultaneous inhibitors (crizotinib, olaparib), the renal excretion and efficacy of metformin may be affected.
Therefore, when metformin and these drugs are administered together, the blood concentration of metformin may increase, so caution is needed, especially in patients with renal impairment. Because OCT inhibitors/inducers may change the efficacy of metformin, dose adjustment of metformin may be considered if necessary.
In addition, nonsteroidal anti-inflammatory drugs (NSAIDs), including selective COX-II (Cyclo-oxygenase) inhibitors, angiotensin-converting enzyme inhibitors (ACE inhibitors), angiotensin II receptor antagonists, and diuretics (especially loop diuretics) may have an adverse effect on renal function and increase the risk of lactic acidosis. Therefore, renal function should be carefully monitored when administered in combination with metformin. Must observe.
(8) Others: In single-dose co-administration studies in healthy volunteers, the pharmacokinetic properties of metformin and propranolol and metformin and ibuprofen were not affected by each other.
Metformin's binding to plasma proteins is negligible, so compared to sulfonylureas, which are extensively bound to plasma proteins, it has little interaction with drugs that are heavily bound to proteins, such as salicylates, sulfonamides, chloramphenicol, and probenecid.
7. Administration to pregnant and lactating women
There are no appropriate clinical trial results for this drug in pregnant and lactating women, so use of this drug during pregnancy or lactation is not recommended.
Information on the individual ingredients is as follows.
1) Pregnant women:
(1) Dapagliflozin: There is no data on the administration of dapagliflozin to pregnant women. Studies on rats showed toxicity to kidney development during the second and third trimesters of human pregnancy. The use of dapagliflozin in pregnant women is not recommended. Once pregnancy is confirmed, dapagliflozin administration should be discontinued.
The effects of dapagliflozin on human fertility have not been studied. In male and female rats, dapagliflozin showed no effects on fertility at any of the doses studied.
(2) Sitagliptin: There are no controlled test results in pregnant women, so its use in pregnant women is not recommended.
(3) Metformin: Uncontrolled hyperglycemia during the periconceptional phase and pregnancy is associated with an increased risk of congenital abnormalities, miscarriage, pregnancy-induced hypertension, preeclampsia, and perinatal mortality. It is important to keep blood sugar levels as close to normal as possible throughout pregnancy to reduce the risks associated with high blood sugar during pregnancy.
Metformin crosses the placenta, and levels of transplacental passage can be as high as maternal concentrations.
Based on data (>1000 exposures) from various studies (clinical studies, register-based cohort studies, meta-analyses, etc.) on metformin use in the periconceptional phase and during pregnancy, no increased risk of congenital abnormalities and/or fetal/neonatal toxicity due to metformin exposure during the periconceptional phase and/or pregnancy has been identified.
Babies exposed to metformin in utero may be small for gestational age. There is limited evidence on the effects of metformin on long-term birth weight outcomes and metabolic complications in infants. It does not appear to affect motor-social development up to 4 years of age, but results beyond 4 years of age are limited.
If you are planning to become pregnant or are clinically necessary for the purpose of controlling blood sugar levels during pregnancy, the use of metformin may be considered in addition to or as an alternative to insulin.
However, pregnant women at risk for placental insufficiency, preeclampsia, or intrauterine growth retardation should not begin treatment with metformin. Fetal development should be closely monitored to prevent birth weight loss, and metformin administration should be discontinued if fetal growth retardation is confirmed.
2) Nursing mothers
(1) Dapagliflozin: It is not known whether dapagliflozin and its metabolites are transferred into human milk. Pharmacodynamic/toxicological data in animals indicate excretion of dapagliflozin/metabolite in milk and pharmacologically mediated effects in nursing offspring. Risk to neonates/infants cannot be excluded. Dapagliflozin should not be used during breastfeeding.
(2) Sitagliptin: Sitagliptin is reported to be secreted into milk and plasma at a ratio of 4:1 in rats, so it is not administered to nursing mothers.
(3) Metformin: Metformin is secreted into breast milk, and no adverse reactions to metformin have been reported in newborns/infants. However, because reported study results are limited, breastfeeding during treatment with metformin is not recommended. Considering the benefits of breastfeeding, the importance of the drug to the nursing mother, and the potential risk of adverse reactions in the infant, a decision should be made whether to discontinue breastfeeding or drug treatment.
8. Administration to children
Safety and efficacy in pediatric patients under 18 years of age have not been established.
9. Administration to elderly people
Elderly people generally have decreased physiological functions, such as liver and kidney function, due to aging, and are likely to be taking drugs that are likely to cause changes in renal function (e.g., antihypertensive drugs that can cause changes in renal function, such as angiotensin-converting enzyme inhibitors (ACE-I) and angiotensin II receptor inhibitors (ARB)). Elderly patients may be at higher risk for volume loss and are more likely to be taking diuretics. When administering this drug to the elderly, dosage adjustment may be necessary based on renal function, and the patient's condition should be observed and administered with caution.
Among these drugs, sitagliptin is mostly excreted through the kidneys, so caution is required when selecting the dosage in elderly patients. The dose of metformin should be set to the minimum dose that can achieve appropriate blood sugar control effects based on the patient's renal function (refer to the section on patients with renal impairment in Dosage and Administration), and the maximum dose is generally not administered to the elderly.
It is recommended to evaluate renal function and body fluid status before and after administration of this drug in elderly patients.
10. Treatment in case of overdose
1) Dapagliflozin
Dapagliflozin did not show any toxicity at single oral doses of up to 500 mg (50 times the maximum recommended human dose) in healthy subjects. These subjects had detectable urinary glucose throughout the treatment period (more than 5 days for the 500 mg dose), no dehydration, hypotension, or electrolyte imbalances were reported, and there were no clinically significant effects on the QTc interval. The incidence of hypoglycemia was similar to placebo. In a clinical trial in which healthy subjects and patients with type 2 diabetes were administered up to 100 mg once daily for 2 weeks (10 times the maximum recommended human dose), the incidence of hypoglycemia was slightly higher than in the placebo group and was not dose-related. Rates of adverse events, including dehydration or hypotension, were similar to the placebo group, and there were no clinically meaningful dose-related changes in laboratory parameters, including serum electrolytes and biomarkers of renal function.
If overdose occurs, appropriate symptomatic treatment should be administered according to the patient's clinical condition. Elimination of dapagliflozin by dialysis has not been studied.
2) Sitagliptin
In clinical trials of sitagliptin, a single dose of up to 800 mg of sitagliptin was administered to healthy adults. In one study administering 800 mg of sitagliptin, an increase in mean QTc of up to 8.0 msec was observed, but this is not believed to be clinically relevant. There is no experience administering doses exceeding 800 mg in humans.
In case of overdose, general symptomatic treatment is administered (e.g., removal of unabsorbed drug from the gastrointestinal tract and clinical monitoring including electrocardiogram), and auxiliary treatment is provided depending on the patient's condition.
Sitagliptin can be partially removed by dialysis. In clinical trials, approximately 13.5% of the administered dose was removed during hemodialysis over 3 to 4 hours. Long-term hemodialysis should be considered if clinically appropriate. It is not known whether sitagliptin is removed by peritoneal dialysis.
3) Metformin
Even if metformin hydrochloride is administered up to 85g, hypoglycemia does not occur even if lactic acidosis occurs in this condition. Metformin is dialyzed with clearance rates reaching 170 mL/min under favorable hemodynamic conditions. Therefore, hemodialysis may be useful to remove accumulated drug in patients suspected of overdosing on metformin.
11. Storage and handling precautions
1) Store out of reach of children.
2) It is not advisable to change the container as it may damage the quality of the product or cause an accident. Store in original container.
12. Information for professionals
*Refer to attached document
5. How to save
Airtight container, stored at room temperature (1~30℃)
6. Packaging unit
30 tablets/bottle
7. Period of use
30 months from date of manufacture